---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence. Covers EMBARQ-CSU1, EMBARQ-CSU2, CDX0159-17, CDX0159-06, and CDX0159-02. 300 evidence topics quoted from 37 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 EMBARQ-CSU1

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov brief summary

> “The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-3.1.1.1-2"></a>

###### Official title in the ClinicalTrials.gov record

> “A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU1)”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-3.1.1.1-3"></a>

###### Aim of the two phase 3 trials stated by the company

> “The Phase 3 Program is designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

> “Active, not recruiting”
> “Study Start (Actual) 2024-07-11”
> “Primary Completion (Actual) 2026-08-12”
> “Study Completion (Estimated) 2027-06”
> “First Posted 2024-06-06”
> “Last Update Posted 2026-11-12”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-3.1.1.2-2"></a>

###### Number of locations and EU trial number in the ClinicalTrials.gov record

> “This study has 235 locations”
> “2024-513208-32-00 ( EU Trial (CTIS) Number )”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-3.1.1.2-3"></a>

###### Initiation of the phase 3 trials in July 2024

> “HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its global Phase 3 program, consisting of two Phase 3 trials (EMBARQ-CSU1 and EMBARQ-CSU2) designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment.”

Source: [Celldex EMBARQ-CSU initiation release (2024)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-initiates-global-phase-3-program)

<a id="topic-3.1.1.2-4"></a>

###### Completion of enrollment in February 2026 and countries and sites across EMBARQ-CSU1 and EMBARQ-CSU2

> “HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the completion of enrollment in the Company’s global Phase 3 program of barzolvolimab in chronic spontaneous urticaria (CSU), which consists of two Phase 3 trials—EMBARQ-CSU1 and EMBARQ-CSU2.”
> “The studies included 43 countries and over 500 sites.”

Source: [Celldex EMBARQ-CSU enrollment release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-completes-enrollment-global-phase-3-studies-embarq-csu1)

<a id="topic-3.1.1.2-5"></a>

###### Data cutoff for the topline results

> “Data cutoff: September 9, 2026”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.1.2-6"></a>

###### Treatment continuing to 52 weeks with 16 weeks of follow-up

> “Patients continue to be treated through 52 weeks, and will be followed for 16 weeks after completion of treatment.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Design in the ClinicalTrials.gov record

> “Allocation : Randomized”
> “Interventional Model : Parallel Assignment”
> “Masking : Quadruple”
> “This is a global, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study investigating the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who are symptomatic despite treatment with non-sedating second generation H1-antihistamines at 1-4 times the locally approved dose.”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-3.1.1.3-2"></a>

###### Study periods in the ClinicalTrials.gov record

> “There is a screening period of up to 4 weeks, followed by a 24-week placebo-controlled treatment period, a 28-week active treatment period where all participants receive barzolvolimab followed by a 16-week treatment free period.”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-3.1.1.3-3"></a>

###### Randomization ratio and study periods in the topline presentation

> “Two randomized, double-blind, placebo-controlled, parallel group studies in moderate to severe CSU”
> “1:1:1”
> “24 Week Placebo Controlled Treatment Period”
> “28 Week Active Treatment Period”
> “16 Week Follow Up Period”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.1.3-4"></a>

###### Randomization, placebo period of 24 weeks, and re-randomization of placebo participants in the topline release

> “Both Phase 3 trials are randomized, double-blind, placebo-controlled, parallel group, global studies.”
> “1,939 patients were randomized (n=963 EMBARQ-CSU1; n=976 EMBARQ-CSU2) evenly to barzolvolimab 150 mg every 4 weeks (following 300 mg loading dose), barzolvolimab 300 mg every 8 weeks (following 450 mg loading dose) for 52 weeks or placebo for 24 weeks.”
> “At 24 weeks, patients on placebo were re-randomized to active treatment across both dosing groups.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.1.3-5"></a>

###### Placebo for 52 weeks and 16-week follow-up in the Form 10-Q

> “Both Phase 3 trials are randomized, double-blind, placebo-controlled, parallel group, global studies where patients have been randomized evenly per trial to barzolvolimab 150 mg every 4 weeks (following 300 mg loading dose), barzolvolimab 300 mg every 8 weeks (following 450 mg loading dose) or placebo for 52 weeks.”
> “At 24 weeks, patients on placebo are re-randomized to active treatment across both dosing groups.”
> “After completion of the 52 week treatment period, patients on study are followed for 16 weeks.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.1.3-6"></a>

###### Timing of the primary endpoint analysis at 24 weeks

> “The primary endpoint analysis was performed when all patients completed the placebo controlled portion of the study at 24 weeks.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.1.3-7"></a>

###### Entry into the phase 3b long-term extension after the trial

> “A global Phase 3b long term extension study (LTE) has been established and is ongoing, which patients can enter following completion of the EMBARQ-CSU Phase 3 trials.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Key inclusion criteria in the ClinicalTrials.gov record

> “Males and females, >/= 18 years of age.”
> “Chronic spontaneous urticaria (CSU) >/= 6 months prior to Screening (Visit 1).”
> “The presence of hives for >/= 6 weeks at any time prior to Visit 1 despite the use of non-sedating H1-antihistamines.”
> “Must be on a stable regimen of second generation non-sedating H1-antihistamine for >/= 4 weeks prior to study treatment.”
> “UAS7 of >/= 16 and ISS7 of >/= 8 during the 7 days prior to study treatment.”
> “Normal blood counts and liver function tests.”
> “Both males and females of child-bearing potential must agree to use highly effective contraceptives during the study and for 150 days after treatment.”
> “Participants with and without prior biologic experience are eligible.”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-3.1.1.4-2"></a>

###### Key exclusion criteria in the ClinicalTrials.gov record

> “Women who are pregnant or nursing.”
> “Chronic urticaria whose predominant manifestation is due to CIndU.”
> “Other diseases associated with urticaria.”
> “Active pruritic skin condition in addition to CSU.”
> “Known HIV, hepatitis B or hepatitis C infection.”
> “Vaccination of a live vaccine within 30 days prior to Screening (Visit 1) (subjects must agree to avoid live vaccinations during the study).”
> “History of anaphylaxis.”
> “Prior treatment with barzolvolimab.”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-3.1.1.4-3"></a>

###### Population summarized in the topline presentation

> “Antihistamine refractory CSU, (1-4x approved dose) including patients with advanced therapy experienced/refractory CSU”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Arms and interventions in the ClinicalTrials.gov record

| Arm | Description in the record |
| --- | --- |
| Barzolvolimab 150 mg | “barzolvolimab given once as a 300 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 52 weeks” |
| Barzolvolimab 300 mg | “barzolvolimab given once as a 450 mg subcutaneous injection followed by 300 mg administered every 8 weeks for 52 weeks” |
| Placebo then barzolvolimab 150 mg | “Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 300 mg followed by 150 mg administered every 4 weeks for 28 weeks.” |
| Placebo then barzolvolimab 300 mg | “Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 450 mg followed by 300 mg administered every 8 weeks for 28 weeks.” |
| Barzolvolimab intervention | “Subcutaneous Administration” |
| Placebo intervention | “Matching placebo Subcutaneous Administration” |

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-3.1.1.5-2"></a>

###### Arms with loading doses in the topline presentation

> “Arm 1 Barzolvolimab 300 mg LD + 150 mg Q4 WK”
> “Arm 2 Barzolvolimab 450 mg LD + 300 mg Q8 WK”
> “Arm 3 Placebo Q4 WK”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Weekly Urticaria Activity Score as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary endpoint and definition of the UAS7 in the ClinicalTrials.gov record

> “Mean change from baseline to Week 12 of UAS7 (Urticaria Activity Score)”
> “The UAS7 is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42, and a minimum possible score of 0.”
> “From Day 1 (first dose) to Day 85 (Week 12)”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-3.1.1.6.1-2"></a>

###### Secondary outcome measures in the current ClinicalTrials.gov record

> “Mean change from baseline to Week 12 of ISS7 (Itch Severity Score)”
> “The ISS7 is the itch severity score for 7 days, the scores range from 0 to 21.”
> “Mean change from baseline to Week 12 of HSS7 (Hives Severity Score)”
> “The HSS7 score is the wheal/hives severity score for 7 days, the scores range from 0 to 21.”
> “Percentage of participants with UAS7 = 0 at Week 12”
> “Proportion of participants who achieve complete absence of hives and itch (UAS7 = 0) at Week 12.”
> “Percentage of participants with UAS7 ≤ 6 at Week 12”
> “Proportion of participants who achieve control of their urticaria signs and symptoms (UAS7≤6) at Week 12.”
> “Percentage of participants with AAS7 > 0 at baseline with AAS7 = 0 at Week 12”
> “Angioedema Activity Score over 7 days [AAS7] describes the effect of angioedema on five categories with 0 being none and 3 being most severe. The final score is calculated by adding together daily scores which can range from 0-15 for 7 days. The resulting maximum score is then 105.”
> “Mean change from baseline in UAS7 in participants refractory to omalizumab treatment at Week 12”
> “Proportion of participants with UAS7 = 0 in participants refractory to omalizumab treatment at Week 12”
> “Incidence of Treatment-Emergent Adverse Events”
> “From Day 1 (first dose) to Day 477 (Week 68)”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-3.1.1.6.1-3"></a>

###### Secondary outcome amendment of February 2026: version 1 compared with version 18 in the record history

> “Comparing V1 (2024-05-31) to V18 (2026-02-12)”
> “Percentage of participants with AAS7 > 0 at baseline with AAS7 = 0 at Week 12”
> “Mean change from baseline in UAS7 at Week 4”
> “[Time Frame: From Day 1 (first dose) to Day 29 (Week 4)]”
> “Mean change from baseline in UAS7 at Week 24”
> “Percentage of participants with UAS7 = 0 at Week 24”
> “[Time Frame: From Day 1 (first dose) to Day 169 (Week 24)]”

Source: [ClinicalTrials.gov NCT06445023 record history](https://clinicaltrials.gov/study/NCT06445023?tab=history&a=1&b=18)

<a id="topic-3.1.1.6.1-4"></a>

###### Key secondary endpoints at Week 12 in the topline presentation

> “Primary Endpoint: mean change from baseline in UAS7 at Week 12”
> “Mean change from baseline in ISS7 and HSS7”
> “Proportion of participants with UAS7=0”
> “Proportion of participants with UAS7≤6”
> “Proportion of participants with AAS7=0 who have AAS7> 0 at baseline”
> “Mean change from baseline in UAS7 in participants refractory to omalizumab”
> “Proportion of participants with UAS7=0 in participants refractory to omalizumab”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.1.6.1-5"></a>

###### Complete response (UAS7=0) as the treatment goal stated by the company

> “Current clinical guidelines recommend complete response (UAS7=0) as the goal of treatment and achieving complete response is directly correlated to the greatest improvements in quality of life for patients.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.1.6.1-6"></a>

###### Reason given by the company for presenting complete response at Week 24

> “Given the importance of Complete Response (complete absence of itch and hives) to patients and physicians”
> “the Company is presenting UAS7=0 data observed at both 12 and 24 weeks.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned enrollment in the ClinicalTrials.gov record

> “Approximately 915 adult participants (610 in the active arms and 305 in the placebo arm) will be randomly assigned to the treatment arms.”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-3.1.1.7.1-2"></a>

###### Planned enrollment per trial at initiation

> “Both Phase 3 trials are randomized, double-blind, placebo-controlled, parallel group, global studies where approximately 915 patients will be randomized evenly to barzolvolimab 150 mg every 4 weeks (following 300 mg loading dose), barzolvolimab 300 mg every 8 weeks (following 450 mg loading dose) or placebo for 52 weeks.”

Source: [Celldex EMBARQ-CSU initiation release (2024)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-initiates-global-phase-3-program)

<a id="topic-3.1.1.7.1-3"></a>

###### Statistical power for the primary endpoint

> “90% powered to detect at least a 10-point difference between each of active arm vs placebo in overall population as well as in the subpopulation of omalizumab refractory participants”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.1.7.1-4"></a>

###### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 963”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-3.1.1.7.1-5"></a>

###### Participants randomized in the topline release

> “1,939 patients were randomized (n=963 EMBARQ-CSU1; n=976 EMBARQ-CSU2)”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.1.7.1-6"></a>

###### Participants analyzed per arm in the full analysis set

> “Mean (SD) unless otherwise indicated; full analysis set”
> “Placebo Q4W (N=325)”
> “Barzolvolimab 150 mg Q4W (N=320)”
> “Barzolvolimab 300 mg Q8W (N=318)”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Full analysis set and primary endpoint model

> “Full analysis set; imputed data and MMRM model”
> “Mean (SD) unless otherwise indicated; full analysis set”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.1.7.2-2"></a>

###### Adjusted proportions from logistic regression with multiple imputation

> “Adjusted proportions are based on logistic regression model with multiple imputation method.”
> “The adjusted odds ratios and the proportions are based on logistic regression model with multiple imputation method.”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.1.7.2-3"></a>

###### Basis of the p-values in the topline release

> “P-values are for LS Mean treatment difference versus placebo.”
> “P-values are based on adjusted odds ratio of logistic regression models.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.1.7.2-4"></a>

###### Definition of the omalizumab-refractory subpopulation

> “Patients treated with omalizumab at approved doses for at least 3 months and whose symptoms never responded or who responded initially but symptoms subsequently returned, or who discontinued omalizumab due to intolerance”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Participants randomized and enrollment status

> “1,939 patients were randomized (n=963 EMBARQ-CSU1; n=976 EMBARQ-CSU2)”
> “The EMBARQ-CSU trials are ongoing, with treatment continuing through 52 weeks.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Baseline characteristics in the full analysis set

> “Mean (SD) unless otherwise indicated; full analysis set”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

| Characteristic | Placebo every 4 weeks (N=325) | Barzolvolimab 150 mg every 4 weeks (N=320) | Barzolvolimab 300 mg every 8 weeks (N=318) |
| --- | --- | --- | --- |
| Age (years), mean (SD) | “46.4 (14.58)” | “46.1 (14.49)” | “47.0 (14.7)” |
| Female, n (%) | “235 (72.3)” | “243 (75.9)” | “228 (71.7)” |
| Race, White, n (%) | “228 (70.2)” | “233 (72.8)” | “216 (67.9)” |
| Race, Black, n (%) | “35 (10.8)” | “39 (12.2)” | “31 (9.7)” |
| Race, Asian, n (%) | “40 (12.3)” | “30 (9.4)” | “47 (14.8)” |
| Weight (kg), mean (SD) | “79.9 (20.47)” | “79.39 (16.98)” | “78.34 (18.06)” |
| UAS7 score, mean (SD) | “30.9 (7.32)” | “30.6 (7.44)” | “30.3 (7.01)” |
| Severe disease (UAS7 of 28 or more), n (%) | “216 (66.5)” | “213 (66.6)” | “216 (67.9)” |
| Omalizumab refractory, n (%) | “55 (16.9)” | “52 (16.3)” | “52 (16.4)” |
| AAS7 greater than 0, n (%) | “237 (72.9)” | “238 (74.4)” | “239 (75.2)” |
| AAS7 in participants with AAS7 greater than 0, mean (SD) | “57.1 (29.99)” | “52.0 (29.15)” | “54.9 (28.24)” |
| DLQI score, mean (SD) | “16.0 (7.34)” | “15.5 (7.13)” | “15.6 (7.13)” |

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Primary endpoint: LS mean change from baseline in UAS7 at Week 12 with standard error

> “Primary Endpoint: Mean Change from Baseline in UAS7 at Week 12:”
> “LS Mean Change (SE) at Week 12”
> “P-values are for LS Mean treatment difference versus placebo.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Arm | Baseline UAS7 | LS mean change (SE) at Week 12 |
| --- | --- | --- |
| Placebo every 4 weeks | “30.9” | “-10.7 (0.65)” |
| Barzolvolimab 150 mg every 4 weeks | “30.6” | “-20.2 (0.64) (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “30.3” | “-20.5 (0.65) (p<.00001)” |

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.1.8.3-2"></a>

###### Primary endpoint: treatment difference in UAS7 change at Week 12 with 97.5% CI, full analysis set

> “Treatment Difference LS Mean (97.5% CI):”
> “Full analysis set; imputed data and MMRM model”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

| Comparison with placebo | Treatment difference, LS mean (97.5% CI) | P-value |
| --- | --- | --- |
| Barzolvolimab 150 mg every 4 weeks | “-9.5 (-11.5, -7.4)” | “p <.00001” |
| Barzolvolimab 300 mg every 8 weeks | “-9.8 (-11.9, -7.8)” | “p <.00001” |

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.1.8.3-3"></a>

###### Complete response (UAS7=0) at Week 12, adjusted proportions

> “Proportion of Patients with Complete Response (UAS7=0) at Weeks 12 and 24”
> “P-values are based on adjusted odds ratio of logistic regression models.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Arm | Complete response (UAS7=0) at Week 12 |
| --- | --- |
| Placebo every 4 weeks | “9.3%” |
| Barzolvolimab 150 mg every 4 weeks | “42.4% (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “42.1% (p<.00001)” |

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

> “Adjusted Proportion* (%) (95% CI) of Participants Achieving UAS7=0 at Week 12”
> “Adjusted proportions are based on logistic regression model with multiple imputation method.”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.1.8.3-4"></a>

###### Complete response (UAS7=0) at Week 24 presented by the company

> “the Company is presenting UAS7=0 data observed at both 12 and 24 weeks.”
> “P-values are based on adjusted odds ratio of logistic regression models.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Arm | Complete response (UAS7=0) at Week 24 |
| --- | --- |
| Placebo every 4 weeks | “15.4%” |
| Barzolvolimab 150 mg every 4 weeks | “49.0% (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “45.1% (p<.00001)” |

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.1.8.3-5"></a>

###### Complete response (UAS7=0) at Week 12 in omalizumab-refractory participants

> “Proportion of Patients with Complete Response (UAS7=0) at Week 12 in Omalizumab-Refractory CSU”
> “P-values are based on adjusted odds ratio of logistic regression models.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Arm | Complete response (UAS7=0) at Week 12, omalizumab refractory |
| --- | --- |
| Placebo every 4 weeks | “9.3%” |
| Barzolvolimab 150 mg every 4 weeks | “55.3% (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “44.3% (p=.00017)” |

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

> “Adjusted Proportion* (95% CI) of Participants Achieving UAS7=0 at Week 12 (Omalizumab Refractory)”
> “Placebo (N=55)”
> “Barzovolimab 150 mg Q4W (N=52)”
> “Barzovolimab 300 mg Q8W (N=52)”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.1.8.3-6"></a>

###### AAS7=0 at Week 12 in participants with baseline AAS7>0

> “Proportion of Patients with AAS7=0 at Week 12 in Patients with Baseline AAS7>0”
> “P-values are based on adjusted odds ratio of logistic regression models.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Arm | AAS7=0 at Week 12, baseline AAS7 greater than 0 |
| --- | --- |
| Placebo every 4 weeks | “33.8%” |
| Barzolvolimab 150 mg every 4 weeks | “62.7% (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “66.3% (p<.00001)” |

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

> “Adjusted Proportion* (95% CI) of Participants Achieving AAS7=0 at Week 12”
> “Placebo (N=237)”
> “Barzovolimab 150 mg Q4W (N=238)”
> “Barzovolimab 300 mg Q8W (N=239)”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.1.8.3-7"></a>

###### Other key secondary endpoints at Week 12 reported as met without values

> “All key secondary endpoints in both EMBARQ-CSU trials were met at Week 12 with high statistical significance and were clinically meaningful.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

> “Trials met key additional secondary endpoints demonstrating consistent and deep responses to barzolvolimab”
> “Mean change from baseline in ISS7 and HSS7”
> “Mean change from baseline in UAS7 in patients refractory to omalizumab”
> “Proportion of patients with UAS7≤6”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Safety statement through the 24-week placebo-controlled period

> “Barzolvolimab was well-tolerated and demonstrated a favorable safety profile consistent with prior experience through the end of the placebo controlled period at Week 24.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.1.8.5-2"></a>

###### Adverse events through the 24-week placebo-controlled period, pooled EMBARQ-CSU1 and EMBARQ-CSU2

> “Adverse Events Through 24 Week Placebo Controlled Period (AEs observed in > 3% of patients)”
> “Pooled EMBARQ-CSU1 and EMBARQ-CSU2”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

| Event, N (%) | Placebo every 4 weeks (N=645) | Barzolvolimab 150 mg every 4 weeks (N=648) | Barzolvolimab 300 mg every 8 weeks (N=641) |
| --- | --- | --- | --- |
| Participants with at least 1 adverse event | “340 (52.7)” | “490 (75.6)” | “492 (76.8)” |
| Hair color changes | “29 (4.5)” | “292 (45.1)” | “330 (51.5)” |
| Skin hypopigmentation | “16 (2.5)” | “71 (11.0)” | “64 (10.0)” |
| Neutropenia | “4 (0.6)” | “59 (9.1)” | “75 (11.7)” |
| Skin hyperpigmentation | “5 (0.8)” | “59 (9.1)” | “58 (9.1)” |
| Dysgeusia | “9 (1.4)” | “44 (6.8)” | “63 (9.8)” |
| Hypogeusia | “10 (1.6)” | “33 (5.1)” | “53 (8.3)” |
| Nasopharyngitis | “36 (5.6)” | “41 (6.3)” | “40 (6.2)” |
| Anemia | “4 (0.6)” | “20 (3.1)” | “20 (3.1)” |
| Participants with serious adverse events | “15 (2.3)” | “6 (0.9)” | “14 (2.2)” |
| Treatment-related serious adverse events | “1 (0.2)” | “3 (0.5)” | “4 (0.6)” |
| Anaphylaxis adjudicated as probable (grade 4) | “0” | “2” | “1 (occurred after placebo dose)” |
| Anaphylaxis, other | “1A” | “1B” | “3C” |

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.1.8.5-3"></a>

###### Footnotes to the other anaphylaxis events, pooled EMBARQ-CSU1 and EMBARQ-CSU2

> “AG3 anaphylaxis adjudicated as unlikely”
> “BG2 angioedema/throat tightness/urticaria”
> “CG3 anemia/neutropenia;”
> “G2 malaise/dyspnea/chest pain;”
> “G3 anaphylaxis after placebo administration adjudicated as unlikely”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.1.8.5-4"></a>

###### Severity and serious adverse events, pooled EMBARQ-CSU1 and EMBARQ-CSU2

> “On barzolvolimab, the vast majority of AEs are mild to moderate”
> “Rate of SAEs similar across treatment groups”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.1.8.5-5"></a>

###### Infections and neutropenia, pooled EMBARQ-CSU1 and EMBARQ-CSU2

> “No increased rates of infection in barzolvolimab vs placebo treatment groups”
> “Placebo: 23.9%”
> “150 mg Q4W: 24.4%”
> “300 mg Q8W: 23.6%”
> “Rates of neutropenia in Phase 3 were consistent with Phase 2”
> “Neutropenia Not Associated with Increased Incidence of Infections”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary: limitations of the available EMBARQ-CSU1 evidence

- Results are available as “topline results” in a company press release and investor presentation (data cutoff September 9, 2026). No peer-reviewed publication is cited, and the ClinicalTrials.gov record lists the trial as active, not recruiting, with study completion estimated for 2027-06. The company anticipates additional 24-week phase 3 results in February 2027.
- The record history comparing version 1 (2024-05-31) with version 18 (2026-02-12) shows changes to the secondary outcomes involving AAS7=0 at Week 12, UAS7 change at Week 4, UAS7 change at Week 24, and UAS7=0 at Week 24. The current record lists secondary outcomes at Week 12, with adverse events to Week 68, and lists no Week 4 or Week 24 UAS7 outcome. The Week 24 UAS7=0 results (15.4%, 49.0%, and 45.1%) are presented by the company, which cites the importance of complete response to patients and physicians.
- Of the key secondary endpoints listed in the company presentation, values are reported for UAS7=0 overall and in omalizumab-refractory participants and for AAS7=0. ISS7 and HSS7 change, UAS7≤6, and UAS7 change in omalizumab-refractory participants are reported as met, without values.
- Placebo participants were re-randomized to barzolvolimab at Week 24, so the placebo comparison ends at Week 24. The sources state the placebo duration differently: the topline release gives “placebo for 24 weeks” and the Form 10-Q gives “placebo for 52 weeks”.
- Adverse events are reported pooled across EMBARQ-CSU1 and EMBARQ-CSU2 through Week 24, with no trial-level counts, no counts of discontinuation for adverse events, and no antidrug antibody results.
- Baseline DLQI is reported (mean 16.0, 15.5, and 15.6), but no DLQI or other health-related quality of life result after baseline is reported.
- The omalizumab-refractory subpopulation comprised 55, 52, and 52 participants (16.9%, 16.3%, and 16.4% of each arm). The trial excluded participants with a history of anaphylaxis and required normal blood counts and liver function tests.

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and); [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2); [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023); [ClinicalTrials.gov NCT06445023 record history](https://clinicaltrials.gov/study/NCT06445023?tab=history&a=1&b=18); [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="heading-3.1.2"></a>

#### 3.1.2 EMBARQ-CSU2

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov brief summary

> “The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.1-2"></a>

###### Official title in the ClinicalTrials.gov record

> “A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU2)”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.1-3"></a>

###### Aim of the two phase 3 trials stated by the company

> “The Phase 3 Program is designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

> “Active, not recruiting”
> “Study Start (Actual) 2024-07-19”
> “Primary Completion (Actual) 2026-08-04”
> “Study Completion (Estimated) 2027-06”
> “First Posted 2024-06-12”
> “Last Update Posted 2026-11-12”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.2-2"></a>

###### Number of locations and EU trial number in the ClinicalTrials.gov record

> “This study has 245 locations”
> “2024-513210-36-00 ( EU Trial (CTIS) Number )”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.2-3"></a>

###### Initiation of the phase 3 trials in July 2024

> “HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its global Phase 3 program, consisting of two Phase 3 trials (EMBARQ-CSU1 and EMBARQ-CSU2) designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment.”

Source: [Celldex EMBARQ-CSU initiation release (2024)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-initiates-global-phase-3-program)

<a id="topic-3.1.2.2-4"></a>

###### Completion of enrollment in February 2026 and countries and sites across EMBARQ-CSU1 and EMBARQ-CSU2

> “HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the completion of enrollment in the Company’s global Phase 3 program of barzolvolimab in chronic spontaneous urticaria (CSU), which consists of two Phase 3 trials—EMBARQ-CSU1 and EMBARQ-CSU2.”
> “The studies included 43 countries and over 500 sites.”

Source: [Celldex EMBARQ-CSU enrollment release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-completes-enrollment-global-phase-3-studies-embarq-csu1)

<a id="topic-3.1.2.2-5"></a>

###### Data cutoff for the topline results

> “Data cutoff: September 9, 2026”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.2.2-6"></a>

###### Treatment continuing to 52 weeks with 16 weeks of follow-up

> “Patients continue to be treated through 52 weeks, and will be followed for 16 weeks after completion of treatment.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Design in the ClinicalTrials.gov record

> “Allocation : Randomized”
> “Interventional Model : Parallel Assignment”
> “Masking : Quadruple”
> “This is a global, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study investigating the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who are symptomatic despite treatment with non-sedating second generation H1-antihistamines at 1-4 times the locally approved dose.”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.3-2"></a>

###### Study periods in the ClinicalTrials.gov record

> “There is a screening period of up to 4 weeks, followed by a 24-week placebo-controlled treatment period, a 28-week active treatment period where all participants receive barzolvolimab followed by a 16-week treatment free period.”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.3-3"></a>

###### Randomization ratio and study periods in the topline presentation

> “Two randomized, double-blind, placebo-controlled, parallel group studies in moderate to severe CSU”
> “1:1:1”
> “24 Week Placebo Controlled Treatment Period”
> “28 Week Active Treatment Period”
> “16 Week Follow Up Period”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.3-4"></a>

###### Randomization, placebo period of 24 weeks, and re-randomization of placebo participants in the topline release

> “Both Phase 3 trials are randomized, double-blind, placebo-controlled, parallel group, global studies.”
> “1,939 patients were randomized (n=963 EMBARQ-CSU1; n=976 EMBARQ-CSU2) evenly to barzolvolimab 150 mg every 4 weeks (following 300 mg loading dose), barzolvolimab 300 mg every 8 weeks (following 450 mg loading dose) for 52 weeks or placebo for 24 weeks.”
> “At 24 weeks, patients on placebo were re-randomized to active treatment across both dosing groups.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.2.3-5"></a>

###### Placebo for 52 weeks and 16-week follow-up in the Form 10-Q

> “Both Phase 3 trials are randomized, double-blind, placebo-controlled, parallel group, global studies where patients have been randomized evenly per trial to barzolvolimab 150 mg every 4 weeks (following 300 mg loading dose), barzolvolimab 300 mg every 8 weeks (following 450 mg loading dose) or placebo for 52 weeks.”
> “At 24 weeks, patients on placebo are re-randomized to active treatment across both dosing groups.”
> “After completion of the 52 week treatment period, patients on study are followed for 16 weeks.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.2.3-6"></a>

###### Timing of the primary endpoint analysis at 24 weeks

> “The primary endpoint analysis was performed when all patients completed the placebo controlled portion of the study at 24 weeks.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.2.3-7"></a>

###### Entry into the phase 3b long-term extension after the trial

> “A global Phase 3b long term extension study (LTE) has been established and is ongoing, which patients can enter following completion of the EMBARQ-CSU Phase 3 trials.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Key inclusion criteria in the ClinicalTrials.gov record

> “Males and females, >/= 18 years of age.”
> “Chronic spontaneous urticaria (CSU) >/= 6 months prior to Screening (Visit 1).”
> “The presence of hives for >/= 6 weeks at any time prior to Visit 1 despite the use of non-sedating H1-antihistamines.”
> “Must be on a stable regimen of second generation non-sedating H1-antihistamine for >/= 4 weeks prior to study treatment.”
> “UAS7 of >/= 16 and ISS7 of >/= 8 during the 7 days prior to study treatment.”
> “Normal blood counts and liver function tests.”
> “Both males and females of child-bearing potential must agree to use highly effective contraceptives during the study and for 150 days after treatment.”
> “Participants with and without prior biologic experience are eligible.”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.4-2"></a>

###### Key exclusion criteria in the ClinicalTrials.gov record

> “Women who are pregnant or nursing.”
> “Chronic urticaria whose predominant manifestation is due to CIndU.”
> “Other diseases associated with urticaria.”
> “Active pruritic skin condition in addition to CSU.”
> “Known HIV, hepatitis B or hepatitis C infection.”
> “Vaccination of a live vaccine within 30 days prior to Screening (Visit 1) (subjects must agree to avoid live vaccinations during the study).”
> “History of anaphylaxis”
> “Prior treatment with barzolvolimab”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.4-3"></a>

###### Population summarized in the topline presentation

> “Antihistamine refractory CSU, (1-4x approved dose) including patients with advanced therapy experienced/refractory CSU”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Arms and interventions in the ClinicalTrials.gov record

| Arm | Description in the record |
| --- | --- |
| Barzolvolimab 150 mg | “barzolvolimab given once as a 300 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 52 weeks” |
| Barzolvolimab 300 mg | “barzolvolimab given once as a 450 mg subcutaneous injection followed by 300 mg administered every 8 weeks for 52 weeks” |
| Placebo then barzolvolimab 150 mg | “Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 300 mg followed by 150 mg administered every 4 weeks for 28 weeks.” |
| Placebo then barzolvolimab 300 mg | “Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 450 mg followed by 300 mg administered every 8 weeks for 28 weeks.” |
| Barzolvolimab intervention | “Subcutaneous Administration” |
| Placebo intervention | “Matching placebo Subcutaneous Administration” |

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.5-2"></a>

###### Arms with loading doses in the topline presentation

> “Arm 1 Barzolvolimab 300 mg LD + 150 mg Q4 WK”
> “Arm 2 Barzolvolimab 450 mg LD + 300 mg Q8 WK”
> “Arm 3 Placebo Q4 WK”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Weekly Urticaria Activity Score as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary endpoint and definition of the UAS7 in the ClinicalTrials.gov record

> “Mean change from baseline to Week 12 of UAS7 (Urticaria Activity Score)”
> “The UAS7 is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42, and a minimum possible score of 0.”
> “From Day 1 (first dose) to Day 85 (Week 12)”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.6.1-2"></a>

###### Secondary outcome measures in the current ClinicalTrials.gov record

> “Mean change from baseline to Week 12 of ISS7 (Itch Severity Score)”
> “The ISS7 is the itch severity score for 7 days, the scores range from 0 to 21.”
> “Mean change from baseline to Week 12 of HSS7 (Hives Severity Score)”
> “The HSS7 score is the wheal/hives severity score for 7 days, the scores range from 0 to 21.”
> “Percentage of patients with UAS7=0 at Week 12”
> “Proportion of participants who achieve complete absence of hives and itch (UAS7 = 0) at Week 12.”
> “Percentage of participants with UAS7 ≤ 6 at Week 12”
> “Proportion of participants who achieve control of their urticaria signs and symptoms (UAS7≤6) at Week 12.”
> “Percentage of participants with AAS7 > 0 at baseline with AAS7 = 0 at Week 12”
> “Angioedema Activity Score over 7 days [AAS7] describes the effect of angioedema on five categories with 0 being none and 3 being most severe. The final score is calculated by adding together daily scores which can range from 0-15 for 7 days. The resulting maximum score is then 105.”
> “Mean change from baseline in UAS7 in participants refractory to omalizumab treatment at Week 12”
> “Proportion of participants with UAS7 = 0 in participants refractory to omalizumab treatment at Week 12”
> “Incidence of Treatment-Emergent Adverse Events”
> “From Day 1 (first dose) to Day 477 (Week 68)”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.6.1-3"></a>

###### Secondary outcome amendment of February 2026: version 1 compared with version 18 in the record history

> “Comparing V1 (2024-06-07) to V18 (2026-02-03)”
> “Percentage of participants with AAS7 > 0 at baseline with AAS7 = 0 at Week 12”
> “Mean change from baseline in UAS7 at Week 4”
> “[Time Frame: From Day 1 (first dose) to Day 29 (Week 4)]”
> “Mean change from baseline in UAS7 at Week 24”
> “Percentage of participants with UAS7 = 0 at Week 24”
> “[Time Frame: From Day 1 (first dose) to Day 169 (Week 24)]”

Source: [ClinicalTrials.gov NCT06455202 record history](https://clinicaltrials.gov/study/NCT06455202?tab=history&a=1&b=18)

<a id="topic-3.1.2.6.1-4"></a>

###### Key secondary endpoints at Week 12 in the topline presentation

> “Primary Endpoint: mean change from baseline in UAS7 at Week 12”
> “Mean change from baseline in ISS7 and HSS7”
> “Proportion of participants with UAS7=0”
> “Proportion of participants with UAS7≤6”
> “Proportion of participants with AAS7=0 who have AAS7> 0 at baseline”
> “Mean change from baseline in UAS7 in participants refractory to omalizumab”
> “Proportion of participants with UAS7=0 in participants refractory to omalizumab”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.6.1-5"></a>

###### Complete response (UAS7=0) as the treatment goal stated by the company

> “Current clinical guidelines recommend complete response (UAS7=0) as the goal of treatment and achieving complete response is directly correlated to the greatest improvements in quality of life for patients.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.2.6.1-6"></a>

###### Reason given by the company for presenting complete response at Week 24

> “Given the importance of Complete Response (complete absence of itch and hives) to patients and physicians”
> “the Company is presenting UAS7=0 data observed at both 12 and 24 weeks.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned enrollment in the ClinicalTrials.gov record

> “Approximately 915 adult participants (610 in the active arms and 305 in the placebo arm) will be randomly assigned to the treatment arms.”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.7.1-2"></a>

###### Planned enrollment per trial at initiation

> “Both Phase 3 trials are randomized, double-blind, placebo-controlled, parallel group, global studies where approximately 915 patients will be randomized evenly to barzolvolimab 150 mg every 4 weeks (following 300 mg loading dose), barzolvolimab 300 mg every 8 weeks (following 450 mg loading dose) or placebo for 52 weeks.”

Source: [Celldex EMBARQ-CSU initiation release (2024)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-initiates-global-phase-3-program)

<a id="topic-3.1.2.7.1-3"></a>

###### Statistical power for the primary endpoint

> “90% powered to detect at least a 10-point difference between each of active arm vs placebo in overall population as well as in the subpopulation of omalizumab refractory participants”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.7.1-4"></a>

###### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 976”

Source: [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-3.1.2.7.1-5"></a>

###### Participants randomized in the topline release

> “1,939 patients were randomized (n=963 EMBARQ-CSU1; n=976 EMBARQ-CSU2)”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.2.7.1-6"></a>

###### Participants analyzed per arm in the full analysis set

> “Mean (SD) unless otherwise indicated; full analysis set”
> “Placebo Q4W (N=321)”
> “Barzolvolimab 150 mg Q4W (N=324)”
> “Barzolvolimab 300 mg Q8W (N=321)”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Full analysis set and primary endpoint model

> “Full analysis set; imputed data and MMRM model”
> “Mean (SD) unless otherwise indicated; full analysis set”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.7.2-2"></a>

###### Adjusted proportions from logistic regression with multiple imputation

> “Adjusted proportions are based on logistic regression model with multiple imputation method.”
> “The adjusted odds ratios and the proportions are based on logistic regression model with multiple imputation method.”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.7.2-3"></a>

###### Basis of the p-values in the topline release

> “P-values are for LS Mean treatment difference versus placebo.”
> “P-values are based on adjusted odds ratio of logistic regression models.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.2.7.2-4"></a>

###### Definition of the omalizumab-refractory subpopulation

> “Patients treated with omalizumab at approved doses for at least 3 months and whose symptoms never responded or who responded initially but symptoms subsequently returned, or who discontinued omalizumab due to intolerance”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Participants randomized and enrollment status

> “1,939 patients were randomized (n=963 EMBARQ-CSU1; n=976 EMBARQ-CSU2)”
> “The EMBARQ-CSU trials are ongoing, with treatment continuing through 52 weeks.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Baseline characteristics in the full analysis set

> “Mean (SD) unless otherwise indicated; full analysis set”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

| Characteristic | Placebo every 4 weeks (N=321) | Barzolvolimab 150 mg every 4 weeks (N=324) | Barzolvolimab 300 mg every 8 weeks (N=321) |
| --- | --- | --- | --- |
| Age (years), mean (SD) | “45.7 (14.59)” | “46.2 (14.53)” | “46.2 (14.01)” |
| Female, n (%) | “215 (67.0)” | “229 (70.7)” | “208 (64.8)” |
| Race, White, n (%) | “229 (71.3)” | “225 (69.4)” | “242 (75.4)” |
| Race, Black, n (%) | “6 (1.9)” | “11 (3.4)” | “8 (2.5)” |
| Race, Asian, n (%) | “49 (15.3)” | “54 (16.7)” | “50 (15.6)” |
| Weight (kg), mean (SD) | “80.70 (18.96)” | “78.72 (19.10)” | “79.94 (19.15)” |
| UAS7 score, mean (SD) | “29.3 (7.19)” | “29.7 (6.87)” | “29.6 (7.28)” |
| Severe disease (UAS7 of 28 or more), n (%) | “199 (62.0)” | “203 (62.7)” | “198 (61.7)” |
| Omalizumab refractory, n (%) | “43 (13.4)” | “44 (13.6)” | “42 (13.1)” |
| AAS7 greater than 0, n (%) | “206 (64.2)” | “213 (65.7)” | “217 (67.6)” |
| AAS7 in participants with AAS7 greater than 0, mean (SD) | “50.2 (28.63)” | “51.5 (28.67)” | “51.7 (27.81)” |
| DLQI score, mean (SD) | “14.2 (7.11)” | “14.4 (7.02)” | “14.3 (7.11)” |

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Primary endpoint: LS mean change from baseline in UAS7 at Week 12 with standard error

> “Primary Endpoint: Mean Change from Baseline in UAS7 at Week 12:”
> “LS Mean Change (SE) at Week 12”
> “P-values are for LS Mean treatment difference versus placebo.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Arm | Baseline UAS7 | LS mean change (SE) at Week 12 |
| --- | --- | --- |
| Placebo every 4 weeks | “29.3” | “-11.4 (0.64)” |
| Barzolvolimab 150 mg every 4 weeks | “29.7” | “-20.2 (0.63) (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “29.6” | “-19.7 (0.64) (p<.00001)” |

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.2.8.3-2"></a>

###### Primary endpoint: treatment difference in UAS7 change at Week 12 with 97.5% CI, full analysis set

> “Treatment Difference LS Mean (97.5% CI):”
> “Full analysis set; imputed data and MMRM model”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

| Comparison with placebo | Treatment difference, LS mean (97.5% CI) | P-value |
| --- | --- | --- |
| Barzolvolimab 150 mg every 4 weeks | “-8.9 ( -10.9, -6.9)” | “p <.00001” |
| Barzolvolimab 300 mg every 8 weeks | “-8.3 ( -10.4, -6.3)” | “p < .00001” |

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.8.3-3"></a>

###### Complete response (UAS7=0) at Week 12, adjusted proportions

> “Proportion of Patients with Complete Response (UAS7=0) at Weeks 12 and 24”
> “P-values are based on adjusted odds ratio of logistic regression models.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Arm | Complete response (UAS7=0) at Week 12 |
| --- | --- |
| Placebo every 4 weeks | “12.6%” |
| Barzolvolimab 150 mg every 4 weeks | “45.7% (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “44.0% (p<.00001)” |

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

> “Adjusted Proportion* (%) (95% CI) of Participants Achieving UAS7=0 at Week 12”
> “Adjusted proportions are based on logistic regression model with multiple imputation method.”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.8.3-4"></a>

###### Complete response (UAS7=0) at Week 24 presented by the company

> “the Company is presenting UAS7=0 data observed at both 12 and 24 weeks.”
> “P-values are based on adjusted odds ratio of logistic regression models.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Arm | Complete response (UAS7=0) at Week 24 |
| --- | --- |
| Placebo every 4 weeks | “17.6%” |
| Barzolvolimab 150 mg every 4 weeks | “54.0% (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “48.4% (p<.00001)” |

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.2.8.3-5"></a>

###### Complete response (UAS7=0) at Week 12 in omalizumab-refractory participants

> “Proportion of Patients with Complete Response (UAS7=0) at Week 12 in Omalizumab-Refractory CSU”
> “P-values are based on adjusted odds ratio of logistic regression models.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Arm | Complete response (UAS7=0) at Week 12, omalizumab refractory |
| --- | --- |
| Placebo every 4 weeks | “15.1%” |
| Barzolvolimab 150 mg every 4 weeks | “41.7% (p=.0089)” |
| Barzolvolimab 300 mg every 8 weeks | “46.4% (p=.0036)” |

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

> “Adjusted Proportion* (95% CI) of Participants Achieving UAS7=0 at Week 12 (Omalizumab Refractory)”
> “Placebo (N=43)”
> “Barzovolimab 150 mg Q4W (N=44)”
> “Barzovolimab 300 mg Q8W (N=42)”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.8.3-6"></a>

###### AAS7=0 at Week 12 in participants with baseline AAS7>0

> “Proportion of Patients with AAS7=0 at Week 12 in Patients with Baseline AAS7>0”
> “P-values are based on adjusted odds ratio of logistic regression models.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Arm | AAS7=0 at Week 12, baseline AAS7 greater than 0 |
| --- | --- |
| Placebo every 4 weeks | “33.7%” |
| Barzolvolimab 150 mg every 4 weeks | “74.3% (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “66.2% (p<.00001)” |

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

> “Adjusted Proportion* (95% CI) of Participants Achieving AAS7=0 at Week 12”
> “Placebo (N=206)”
> “Barzovolimab 150 mg Q4W (N=213)”
> “Barzovolimab 300 mg Q8W (N=217)”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.8.3-7"></a>

###### Other key secondary endpoints at Week 12 reported as met without values

> “All key secondary endpoints in both EMBARQ-CSU trials were met at Week 12 with high statistical significance and were clinically meaningful.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

> “Trials met key additional secondary endpoints demonstrating consistent and deep responses to barzolvolimab”
> “Mean change from baseline in ISS7 and HSS7”
> “Mean change from baseline in UAS7 in patients refractory to omalizumab”
> “Proportion of patients with UAS7≤6”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Safety statement through the 24-week placebo-controlled period

> “Barzolvolimab was well-tolerated and demonstrated a favorable safety profile consistent with prior experience through the end of the placebo controlled period at Week 24.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-3.1.2.8.5-2"></a>

###### Adverse events through the 24-week placebo-controlled period, pooled EMBARQ-CSU1 and EMBARQ-CSU2

> “Adverse Events Through 24 Week Placebo Controlled Period (AEs observed in > 3% of patients)”
> “Pooled EMBARQ-CSU1 and EMBARQ-CSU2”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

| Event, N (%) | Placebo every 4 weeks (N=645) | Barzolvolimab 150 mg every 4 weeks (N=648) | Barzolvolimab 300 mg every 8 weeks (N=641) |
| --- | --- | --- | --- |
| Participants with at least 1 adverse event | “340 (52.7)” | “490 (75.6)” | “492 (76.8)” |
| Hair color changes | “29 (4.5)” | “292 (45.1)” | “330 (51.5)” |
| Skin hypopigmentation | “16 (2.5)” | “71 (11.0)” | “64 (10.0)” |
| Neutropenia | “4 (0.6)” | “59 (9.1)” | “75 (11.7)” |
| Skin hyperpigmentation | “5 (0.8)” | “59 (9.1)” | “58 (9.1)” |
| Dysgeusia | “9 (1.4)” | “44 (6.8)” | “63 (9.8)” |
| Hypogeusia | “10 (1.6)” | “33 (5.1)” | “53 (8.3)” |
| Nasopharyngitis | “36 (5.6)” | “41 (6.3)” | “40 (6.2)” |
| Anemia | “4 (0.6)” | “20 (3.1)” | “20 (3.1)” |
| Participants with serious adverse events | “15 (2.3)” | “6 (0.9)” | “14 (2.2)” |
| Treatment-related serious adverse events | “1 (0.2)” | “3 (0.5)” | “4 (0.6)” |
| Anaphylaxis adjudicated as probable (grade 4) | “0” | “2” | “1 (occurred after placebo dose)” |
| Anaphylaxis, other | “1A” | “1B” | “3C” |

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.8.5-3"></a>

###### Footnotes to the other anaphylaxis events, pooled EMBARQ-CSU1 and EMBARQ-CSU2

> “AG3 anaphylaxis adjudicated as unlikely”
> “BG2 angioedema/throat tightness/urticaria”
> “CG3 anemia/neutropenia;”
> “G2 malaise/dyspnea/chest pain;”
> “G3 anaphylaxis after placebo administration adjudicated as unlikely”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.8.5-4"></a>

###### Severity and serious adverse events, pooled EMBARQ-CSU1 and EMBARQ-CSU2

> “On barzolvolimab, the vast majority of AEs are mild to moderate”
> “Rate of SAEs similar across treatment groups”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-3.1.2.8.5-5"></a>

###### Infections and neutropenia, pooled EMBARQ-CSU1 and EMBARQ-CSU2

> “No increased rates of infection in barzolvolimab vs placebo treatment groups”
> “Placebo: 23.9%”
> “150 mg Q4W: 24.4%”
> “300 mg Q8W: 23.6%”
> “Rates of neutropenia in Phase 3 were consistent with Phase 2”
> “Neutropenia Not Associated with Increased Incidence of Infections”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary: limitations of the available EMBARQ-CSU2 evidence

- Results are available as “topline results” in a company press release and investor presentation (data cutoff September 9, 2026). No peer-reviewed publication is cited, and the ClinicalTrials.gov record lists the trial as active, not recruiting, with study completion estimated for 2027-06. The company anticipates additional 24-week phase 3 results in February 2027.
- The record history comparing version 1 (2024-06-07) with version 18 (2026-02-03) shows changes to the secondary outcomes involving AAS7=0 at Week 12, UAS7 change at Week 4, UAS7 change at Week 24, and UAS7=0 at Week 24. The current record lists secondary outcomes at Week 12, with adverse events to Week 68, and lists no Week 4 or Week 24 UAS7 outcome. The Week 24 UAS7=0 results (17.6%, 54.0%, and 48.4%) are presented by the company, which cites the importance of complete response to patients and physicians.
- Of the key secondary endpoints listed in the company presentation, values are reported for UAS7=0 overall and in omalizumab-refractory participants and for AAS7=0. ISS7 and HSS7 change, UAS7≤6, and UAS7 change in omalizumab-refractory participants are reported as met, without values.
- Participant counts are reported from different sources without reconciliation: 976 participants randomized (release) and enrolled (ClinicalTrials.gov), and a full analysis set of N=321, N=324, and N=321 by arm (presentation). The placebo duration also differs: the topline release gives “placebo for 24 weeks” and the Form 10-Q gives “placebo for 52 weeks”. Placebo participants were re-randomized to barzolvolimab at Week 24, so the placebo comparison ends at Week 24.
- Adverse events are reported pooled across EMBARQ-CSU1 and EMBARQ-CSU2 through Week 24, with no trial-level counts, no counts of discontinuation for adverse events, and no antidrug antibody results.
- Baseline DLQI is reported (mean 14.2, 14.4, and 14.3), but no DLQI or other health-related quality of life result after baseline is reported.
- The omalizumab-refractory subpopulation comprised 43, 44, and 42 participants (13.4%, 13.6%, and 13.1% of each arm), with p-values of .0089 and .0036 for UAS7=0 at Week 12 in this subgroup. The trial excluded participants with a history of anaphylaxis and required normal blood counts and liver function tests.

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and); [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2); [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202); [ClinicalTrials.gov NCT06455202 record history](https://clinicaltrials.gov/study/NCT06455202?tab=history&a=1&b=18); [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="heading-3.1.3"></a>

#### 3.1.3 CDX0159-17

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov brief summary

> “The purpose of this extension study is to collect long-term efficacy and safety data on barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who completed the treatment and follow-up periods of the Phase 3 clinical trials.”
> “This study will also fulfill the Celldex commitment to provide post-trial access to participants who have completed the phase 3 studies, where applicable.”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.1-2"></a>

###### Official title in the ClinicalTrials.gov record

> “A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.1-3"></a>

###### Time to disease worsening as the aim in the detailed description

> “This is a global, multicenter, long-term extension phase 3b study to determine the time to disease worsening or treatment failure in adult participants with Chronic Spontaneous Urticaria (CSU) who completed the treatment and follow-up periods the phase 3 clinical trials.”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

> “Enrolling by invitation”
> “Study Start (Actual) 2025-11-25”
> “Primary Completion (Estimated) 2028-09”
> “Study Completion (Estimated) 2028-09”
> “First Posted 2025-12-01”
> “Last Update Posted 2026-11-02”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.2-2"></a>

###### Number of locations in the ClinicalTrials.gov record

> “This study has 201 locations”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.2-3"></a>

###### Long-term extension established and ongoing at the phase 3 topline

> “A global Phase 3b long term extension study (LTE) has been established and is ongoing, which patients can enter following completion of the EMBARQ-CSU Phase 3 trials.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Design in the ClinicalTrials.gov record

> “Allocation : Non-Randomized”
> “Interventional Model : Parallel Assignment”
> “Masking : None (Open Label)”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.3-2"></a>

###### Observation and retreatment groups assigned by UAS7 at entry, and duration of participation

> “The study will consist of 2 Groups: Group 1 (Observation Group), comprising participants whose UAS7 score is less than 16 at entry and Group 2 (Barzolvolimab Retreatment Group) comprising participants whose UAS7 score is 16 or greater.”
> “Participation in this trial will last for approximately 52 weeks for participants assigned to Group 1 (Observation Group) and who do not receive barzolvolimab during the trial. Participants assigned to Group 1 who require barzolvolimab rescue during the trial will be in the trial for up to 68 weeks. Participants assigned to Group 2 (Barzolvolimab Retreatment Group), trial participation will last for approximately 68 weeks from the start of treatment (Day 1).”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.3-3"></a>

###### Observation and retreatment groups described in the Form 10-Q

> “In addition, a global Phase 3b long term extension (LTE) study has been established for patient entry after completion of the EMBARQ - CSU Phase 3 trials.”
> “The study will consist of 2 Groups: Group 1 (Observation Group), containing patients whose disease remains well controlled (UAS7<16) and Group 2 (Barzolvolimab Retreatment Group) containing patients whose disease is currently moderate to severe (UAS7≥16).”
> “Patients in Group 2 will receive up to an additional year of treatment with barzolvolimab.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Key inclusion criteria in the ClinicalTrials.gov record

> “Must have successfully completed the preceding phase 3 clinical trials (CDX0159-12 or CDX0159-13).”
> “Both males and females of child-bearing potential must agree to use highly effective contraceptives when receiving barzolvolimab treatment and for 150 days after treatment.”
> “Willing and able to comply with all study requirements and procedures, including completion of a daily symptom electronic diary.”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.4-2"></a>

###### Key exclusion criteria in the ClinicalTrials.gov record

> “Active pruritic skin condition in addition to CSU.”
> “Medical condition that would cause additional risk or interfere with study procedures.”
> “Participants without at least one documented UAS7 score from Weeks 64-68 of the CDX0159-12 or CDX0159-13 trials.”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Groups and interventions in the ClinicalTrials.gov record

| Group | Description in the record |
| --- | --- |
| Group 1, observation | “Standard of care treatment (at least 2nd generation Type 1 antihistamines [H1AH] with or without other permitted background medications) for 52 weeks.” |
| Group 1, rescue for worsening disease | “For participants with worsening disease (UAS7 score of 16 or greater at any time between Weeks 0-24), barzolvolimab will be administered once as a 300 mg subcutaneous injection followed by 150 mg every 4 weeks for up to 52 weeks.” |
| Group 2, retreatment | “Barzolvolimab given once as a 300 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 52 weeks” |
| Barzolvolimab intervention | “Subcutaneous Administration” |
| Standard of care intervention | “Observational/Standard of Care” |

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.5-2"></a>

###### Treatment of observation group participants whose disease flares in the first 6 months

> “Patients in the observation group (Group 1) whose CSU flares to a UAS7>/=16 in the first 6 months of the LTE will also be able to receive treatment.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Time to Disease Worsening as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Primary outcome measures in the ClinicalTrials.gov record

> “Time to disease worsening or treatment failure through Week 52 based on the occurrence of UAS7 (Urticaria Activity Score) of 16 or greater.”
> “Time to disease worsening or treatment failure through Week 52 based on the occurrence of the discontinuation of barzolvolimab in Group 2 due to lack of efficacy or to a treatment related adverse event.”
> “Time to disease worsening or treatment failure through Week 52 based on the occurrence of first use of strongly confounding prohibited medication (Group 1 or 2) or use of barzolvolimab in Group 1.”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.6.1-2"></a>

###### Definition of the UAS7 in the ClinicalTrials.gov record

> “The UAS7 is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42, and a minimum possible score of 0.”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.6.1-3"></a>

###### Secondary outcome measures for the observation group (Group 1)

> “Group 1: Change from baseline in Urticaria Activity Score (UAS7) at Week 26.”
> “Group 1: Change from baseline in UAS7 at Week 52/End of Study.”
> “Group 1: Proportion of participants who maintained at least well-controlled disease (UAS7 ≤ 6) at Week 26.”
> “Group 1: Proportion of participants who maintained at least well-controlled disease (UAS7 ≤ 6) at Week 52.”
> “Group 1: Proportion of participants with complete absence of hives and itch (UAS7 = 0 AAS7 = 0) at Day 1 who maintained complete control at Week 26.”
> “Group 1: Participants with at least well-controlled disease (UAS7 ≤ 6) at Day 1, time to loss of well-controlled disease through Week 52.”
> “Group 1: Participants with complete absence of hives and itch (UAS7 = 0) at Day 1, time to loss of complete controlled disease through Week 52.”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.6.1-4"></a>

###### Secondary outcome measures for the retreatment group (Group 2)

> “Group 2: Change from baseline in UAS7 at Week 12.”
> “Group 2: Change from baseline in UAS7 at Week 68.”
> “Group 2: Proportion of participants with at least well-controlled disease (UAS7 ≤ 6) at Week 12.”
> “Group 2: Proportion of participants who achieve complete absence of hives and itch (UAS7 = 0) at Week 12.”
> “Group 2: Percentage of participants with UAS7 = 0 at Week 52.”
> “Group 2 Incidence of treatment emergent adverse events.”
> “Group 2 Incidence of treatment emergent adverse events leading to treatment discontinuation.”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.6.1-5"></a>

###### Safety outcome measures for the observation group (Group 1)

> “Group 1 Incidence of adverse events.”
> “Group 1 Incidence of treatment emergent adverse events in participants receiving barzolvolimab retreatment.”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned enrollment in the ClinicalTrials.gov record

> “Enrollment (Estimated) 1370”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

No evidence found.

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary: limitations of the available long-term extension evidence

- The phase 3b long-term extension (NCT07256392) started 2025-11-25, is enrolling by invitation, and has an estimated primary completion of 2028-09. No disposition, baseline, efficacy, quality of life, or safety results have been reported.
- The design is non-randomized and open label. Participants are assigned by UAS7 at entry: those with UAS7 below 16 enter an observation group on standard of care (at least second-generation H1 antihistamines), and those with UAS7 of 16 or greater enter a barzolvolimab retreatment group.
- Retreatment and rescue of observation-group participants with worsening disease both use a 300 mg loading dose followed by 150 mg every 4 weeks; the 300 mg every 8 weeks regimen of the phase 3 trials is not among the extension's interventions.
- Enrollment is limited to participants who completed the preceding phase 3 trials (CDX0159-12 or CDX0159-13) and have at least one documented UAS7 score from Weeks 64 to 68 of those trials.
- The primary endpoint is time to disease worsening or treatment failure through Week 52, defined by UAS7 of 16 or greater, discontinuation of barzolvolimab in the retreatment group for lack of efficacy or a treatment-related adverse event, or first use of a strongly confounding prohibited medication or of barzolvolimab in the observation group. Estimated enrollment is 1370.

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392); [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and); [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="heading-3.1.4"></a>

#### 3.1.4 CDX0159-06

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Objective stated in the primary publication

> “We assessed the efficacy and safety of various dose regimens of barzolvolimab, a mast cell–depleting anti-KIT antibody, in patients with CSU.”
> “Here we report the results of the primary analysis of a large global phase 2 study evaluating the safety and efficacy of barzolvolimab compared to placebo in CSU patients whose disease is inadequately controlled by antihistamines.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.1-2"></a>

###### Purpose stated in the ClinicalTrials.gov record

> “The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Spontaneous Urticaria”

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-3.1.4.1-3"></a>

###### Dose-finding purpose stated by the company

> “The study was a randomized, double-blind, placebo-controlled, parallel group Phase 2 study that evaluated the efficacy and safety profile of multiple dose regimens of barzolvolimab to determine the optimal dosing strategy.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.4.1-4"></a>

###### Objectives of the Week 52, follow-up, and off-treatment analyses

> “Here we present the long-term (week 52) analysis of this Phase 2 study”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

> “Here we present the efficacy and safety of barzolvolimab during the 24-week follow up period”

Source: [Metz et al. (2025b)](https://celldex.com/wp-content/uploads/2025/06/EAACI_Congress_2025-Barzolvolimab-76-Week-LB-FINAL_6.13.25.pdf)

> “The objective of this analysis was to characterize off-treatment efficacy among patients who achieved well-controlled disease (UAS7 ≤ 6) after 52 weeks of barzolvolimab treatment”

Source: [Metz et al. (2026b)](https://celldex.com/wp-content/uploads/2026/02/Barzol_AAAAI-CSU-OT-Analysis-2.27.26.pdf)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Study dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2022-05-19”
> “Primary Completion (Actual) 2023-09-28”
> “Study Completion (Actual) 2024-12-20”

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-3.1.4.2-2"></a>

###### Number of locations in the ClinicalTrials.gov record

> “This study has 56 locations”

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-3.1.4.2-3"></a>

###### Screening dates, last Week 12 visit, and regions in the primary publication

> “From May 19, 2022, to June 15, 2023, a total of 350 patients were screened, of whom 208 were randomly assigned.”
> “the last week 12 visit was September 28, 2023.”
> “The trial included sites in the United States, European Union, and South Africa.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.2-4"></a>

###### Sites and countries stated by the company: 9 countries

> “The study was conducted at approximately 75 clinical trial sites across 9 countries.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.4.2-5"></a>

###### Sites and countries in the 52-week presentation: 10 countries

> “208 patients enrolled at ~75 sites/10 countries”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

<a id="topic-3.1.4.2-6"></a>

###### First participant dosed, June 2022

> “HAMPTON, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the treatment of chronic spontaneous urticaria (CSU).”

Source: [Celldex phase 2 CSU first patient dosed release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-first-patient-dosed-phase-2-study)

<a id="topic-3.1.4.2-7"></a>

###### Interim data cut for the 52-week analysis

> “Results based on interim data cut: July 31, 2024”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Design in the ClinicalTrials.gov record

> “A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Assess the Efficacy and Safety of CDX-0159 in Patients With Chronic Spontaneous Urticaria”
> “Allocation : Randomized Interventional Model : Parallel Assignment Masking : Quadruple”
> “There is a screening period of up to 4 weeks, followed by a 16-week placebo-controlled treatment period (Placebo-Controlled Treatment Phase) where patients will receive either barzolvolimab at a dose level of 75mg, 150mg, or 300mg, or placebo, and then a 36-week treatment period where all patients will receive barzolvolimab.”
> “Patients who receive barzolvolimab 75mg or placebo in the placebo-controlled treatment phase will be re-randomized to receive either barzolvolimab 150mg or 300mg in the active treatment phase.”

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-3.1.4.3-2"></a>

###### Study periods, randomization ratio, and stratification in the primary publication

> “This phase 2, randomized, double-blind, placebo-controlled, parallel-group study (NCT05368285) in patients with CSU refractory to antihistamines assessed the efficacy and safety of barzolvolimab.”
> “The study included the following periods: a 2- to 4-week screening phase, a placebo-controlled treatment phase from baseline to week 16 (16 weeks), an active treatment phase from week 16 to week 52 (36 weeks), and a follow-up phase from week 52 to week 76 (24 weeks).”
> “Patients were randomly assigned in a 1:1:1:1 ratio to receive a subcutaneous injection of either barzolvolimab or placebo (saline) once every 4 or 8 weeks according to their assigned cohort (75 mg every 4 weeks; 150 mg every 4 weeks; 300 mg every 8 weeks) over 16 weeks.”
> “Randomization was stratified by baseline disease severity (UAS7 ≤ 27 [moderate] vs UAS7 > 27 [severe]) and baseline absolute neutrophil count (<3000 μL vs 3,000 μL).”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.3-3"></a>

###### Blinding and unblinded pharmacist

> “After confirmation of treatment assignment, an unblinded pharmacist/authorized delegate prepared and administered the study treatment for each patient.”
> “All patients and study personnel were blinded to the identity of the study drug until the last enrolled patient completed the last study visit.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.3-4"></a>

###### Dose selection based on healthy volunteer modeling

> “Barzolvolimab doses were selected on the basis of safety, pharmacokinetics, pharmacodynamics (serum tryptase), and clinical effect results from completed and ongoing studies of the intravenous and subcutaneous formulations.”
> “Pharmacokinetic/pharmacodynamic modeling and simulation that was based on population parameters in healthy volunteers were used to estimate exposure for the proposed regimens.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.3-5"></a>

###### Re-randomization at Week 16 and off-treatment follow-up

> “At Week 16, the 75 mg Q4W and placebo groups were re-randomized 1:1 to barzolvolimab 150 mg Q4W or 300 mg Q8W for 36 weeks; other patients remained on their original dose”
> “Following the 52-week study period, patients transitioned into a 24-week off-treatment follow-up”

Source: [Metz et al. (2026d)](https://celldex.com/wp-content/uploads/2026/10/FCD-2026_Pigmentation-Changes-Poster_FINAL.pdf)

<a id="topic-3.1.4.3-6"></a>

###### Clinic visits and diaries in each period

> “Patients will complete daily, and weekly diaries and will attend 6 in-clinic visits at Weeks 0, 2, 4, 8, 12 and 16”
> “Patients continue to complete daily and weekly diaries and will attend 9 in-clinic visits at Weeks 20, 24, 28, 32, 36, 40, 44, 48 and 52”
> “Patients continue to complete daily and weekly diaries and will attend 6 in-clinic visits at Weeks 56, 60, 64, 68, 72 and 76”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

<a id="topic-3.1.4.3-7"></a>

###### Design stated by the company

> “208 patients were randomly assigned on a 1:1:1:1 ratio to receive subcutaneous injections of barzolvolimab at 75 mg every 4 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks or placebo during a 16-week placebo-controlled treatment phase.”
> “After 16 weeks, patients then entered a 36-week active treatment period, in which patients receiving placebo or the 75 mg dose were randomized to receive barzolvolimab 150 mg every 4 weeks or 300 mg every 8 weeks; patients already randomized to the 150 mg and 300 mg treatment arms remained on the same regimen as during the placebo-controlled treatment period.”
> “After 52 weeks, patients then entered a follow-up period for an additional 24 weeks.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Key inclusion criteria in the ClinicalTrials.gov record

> “Males and females, >/= 18 years of age.”
> “Diagnosis of chronic spontaneous urticaria (CSU) >/= 6 months.”
> “Must be on a stable regimen of second generation non-sedating H1-antihistamine for >/= 4 weeks prior to study treatment.”
> “UAS7 of >/= 16 and ISS7 of >/= 8 during the 7 days prior to treatment.”
> “Normal blood counts and liver function tests”
> “Both males and females of child-bearing potential must agree to use highly effective contraceptives during the study and for 150 days after treatment.”

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-3.1.4.4-2"></a>

###### Key exclusion criteria in the ClinicalTrials.gov record

> “Women who are pregnant or nursing.”
> “Clearly defined cause for chronic urticaria.”
> “Active, pruritic skin condition in addition to CSU.”
> “Known active HIV, hepatitis B or hepatitis C infection.”
> “Vaccination of a live vaccine within 2 months prior to study treatment (subjects must agree to avoid vaccination during the study).”
> “History of anaphylaxis”
> “Prior treatment with barzolvolimab”

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-3.1.4.4-3"></a>

###### Eligibility in the primary publication, including antihistamine dose and hematology criteria

> “Eligible patients were aged ≥18 years and had CSU refractory to up to 4 times the approved doses of H1AH; patients had to be receiving a stable dose of a single H1AH.”
> “Key inclusion criteria were moderate-to-severe CSU, defined as a weekly urticaria activity score (UAS7) of ≥16”
> “Patients met defined hematology and chemistry criteria (hemoglobin, white blood cell count, absolute neutrophil count, and platelets at or above the lower limit of normal and ≤1.5× the upper limit of normal; aspartate aminotransferase/alanine aminotransferase ≤2× the upper limit of normal and total bilirubin at or below the upper limit of normal at screening visits)”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.4-4"></a>

###### Biologic washout and prior omalizumab in the primary publication

> “Additional key exclusion criteria were receipt of biologic therapy (eg, omalizumab, dupilumab, ligelizumab, or other investigational monoclonal antibodies) within the 3 months before screening visit 1 or prior treatment with barzolvolimab; treatment with immunosuppressives within 4 weeks/5 half-lives”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.4-5"></a>

###### Population described in the congress presentations, including prior biologics

> “Patients with moderate to severe CSU who remain symptomatic despite treatment with up to 4X labeled dose of antihistamines and includes patients with prior biologics”

Source: [Metz et al. (2025b)](https://celldex.com/wp-content/uploads/2025/06/EAACI_Congress_2025-Barzolvolimab-76-Week-LB-FINAL_6.13.25.pdf)

> “The overall clinical trial included 207 patients with moderate to severe antihistamine-refractory CSU (UAS7 of ≥16 and a weekly Itch Severity Score [ISS7] of ≥8 for ≥6 months)”

Source: [Metz et al. (2026c)](https://celldex.com/wp-content/uploads/2026/06/EAACI-2026-Angioedema-Flash-Talk-and-Slides.pdf)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Arms in the ClinicalTrials.gov record

| Arm | Description |
| --- | --- |
| Barzolvolimab 75 mg then 150 mg | “barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 150 mg injection subcutaneous every 4 weeks for 36 weeks” |
| Barzolvolimab 75 mg then 300 mg | “barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 300 mg injection subcutaneous every 8 weeks for 36 weeks” |
| Barzolvolimab 150 mg | “barzolvolimab 150 mg injection subcutaneous every 4 weeks for 52 weeks” |
| Barzolvolimab 300 mg | “barzolvolimab 300 mg injection subcutaneous every 8 weeks for 52 weeks” |
| Placebo then barzolvolimab 150 mg | “Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 150 mg injection subcutaneous every 4 weeks for 36 weeks” |
| Placebo then barzolvolimab 300 mg | “Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 300 mg injection subcutaneous every 8 weeks for 36 weeks” |

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-3.1.4.5-2"></a>

###### Dosing schedule with placebo injections in the every-8-weeks group

> “All patients received treatment on day 1 (baseline) and thereafter every 4 weeks; those randomized to every 8 weeks received placebo injections at the intervening dosing visits.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.5-3"></a>

###### Rescue antihistamine and oral corticosteroids

> “Rescue treatment for patients whose H1AH was at 1 to 3 times the approved dose was additional H1AH, either the same as or different from the background H1AH, not to exceed 4 times the approved dose.”
> “If acute symptoms were still uncontrolled, then a single dose or a short (3 day) course of oral corticosteroids at doses up to prednisone 40 mg (or equivalent) followed by quick tapering was allowed.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.5-4"></a>

###### Last dose at Week 48

> “Last dose of barzolvolimab was at W48”

Source: [Metz et al. (2026b)](https://celldex.com/wp-content/uploads/2026/02/Barzol_AAAAI-CSU-OT-Analysis-2.27.26.pdf)

> “Seven months after the last dose of barzolvolimab (at Week 48), 41% of patients demonstrated a UAS7=0 (complete response) at Week 76”

Source: [Metz et al. (2026d)](https://celldex.com/wp-content/uploads/2026/10/FCD-2026_Pigmentation-Changes-Poster_FINAL.pdf)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Weekly Urticaria Activity Score as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Primary endpoint and UAS7 definition in the ClinicalTrials.gov record

> “Mean change from baseline to Week 12 of UAS7 (Urticaria Activity Score)”
> “UAS7 is the sum of the itch severity score measured over 7 days (ISS7) and the hives severity score measured over 7 days (HSS7). The possible range of UAS7 is 0 - 42.”
> “Itch severity score (ISS) is on a scale of 0 - 3.”
> “Hives severity score (HSS) is on a scale of 0 - 3.”
> “From baseline to Day 85 (Week 12)”

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-3.1.4.6.1-2"></a>

###### Secondary endpoints in the ClinicalTrials.gov record: ISS7, HSS7, and AAS7

> “Mean change from baseline to Week 12 of ISS7 (Itch Severity Score)”
> “Mean change from baseline to Week 12 of HSS7 (Hives Severity Score)”
> “Mean change from baseline to Week 12 of AAS7 (Angioedema Activity Score)”
> “AAS captures the presences of swelling over the last 24 hours and rates the severity with 5 questions. The possible range of the weekly score is 0 - 105.”

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-3.1.4.6.1-3"></a>

###### Complete response as the treatment goal, and UAS7 disease activity categories

> “The goal of CSU therapy is to obtain complete disease response.”
> “Patients with CSU who do not experience complete response to treatment continue to have significant impact of the disease on their quality of life.”
> “(disease activity categories: 0, symptom-free; 1-6, well controlled; 7-15, mild; 16-27, moderate; and 28-42, severe”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

> “Current clinical guidelines recommend complete response (UAS7=0) as the goal of treatment and achieving complete response is directly correlated to the greatest improvements in quality of life for patients.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.4.6.1-4"></a>

###### Secondary and exploratory endpoints in the primary publication, including CSU-free status

> “Secondary and exploratory end points included the mean change and mean percentage change from baseline to week 12 in ISS7, hives severity score over 7 days (HSS7), and Angioedema Activity Score over 7 days (AAS7); the proportion of patients obtaining UAS7 ≤ 6 (well controlled) and UAS7 = 0 (complete response) by week; the proportion of patients obtaining CSU-free status (defined as concurrent ISS7 = 0, HSS7 = 0, and AAS7 = 0) by week; and tryptase serum levels change from baseline to week 12.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.6.1-5"></a>

###### UAS7 health states used for the Week 52 to Week 76 follow-up

> “UAS7 score-based health states were used to describe CSU disease activity throughout the 24-week follow-up period (W52 – W76)”

Source: [Metz et al. (2026b)](https://celldex.com/wp-content/uploads/2026/02/Barzol_AAAAI-CSU-OT-Analysis-2.27.26.pdf)

<a id="topic-3.1.4.6.1-6"></a>

###### Angioedema Activity Score over 7 days: range and dimensions

> “AAS measures 5 dimensions of angioedema (duration, physical discomfort, impact on daily activities, impact on appearance, and overall severity) for the past 24 hours. AAS7 comprises the sum of all AAS dimensions over a 7-day period with scores ranging from 0 to 105, with higher scores indicating more severe symptoms”

Source: [Metz et al. (2026c)](https://celldex.com/wp-content/uploads/2026/06/EAACI-2026-Angioedema-Flash-Talk-and-Slides.pdf)

<a id="topic-3.1.4.6.1-7"></a>

###### AAS7 improvement of more than 8 points as the clinically meaningful threshold

> “Patients on barzolvolimab experienced a > 8 point improvement in AAS7 (considered a clinically meaningful result) across all doses compared to placebo (p<0.05).”

Source: [Celldex phase 2 CSU angioedema release (2024)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-data-demonstrating-profound)

<a id="topic-3.1.4.6.1-8"></a>

###### Urticaria Control Test and Dermatology Life Quality Index: ranges and thresholds

> “Urticaria Control Test (UCT) consists of four questions (on a scale of 0-4; total 0-16) used to assesses symptoms, quality of life, treatment effectiveness and overall disease control in patients with chronic urticaria (spontaneous and inducible). UCT≥12 is well controlled and UCT=16 is complete control.”
> “Dermatology Life Quality Index (DLQI) consists of ten questions (on a scale of 0–3, total 0–30) used to measure the impact of skin disease on patient quality of life related to symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. DLQI 0–1 indicates no effect on a patient’s life.”

Source: [Celldex AAAAI 2026 data release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-presents-additional-positive-data-phase-2-chronic)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Sample size and power in the primary publication

> “A sample size of 168 with 42 patients per group provided 80% power, based on a 2-sided type I error of 0.05, to detect a mean difference in UAS7 from baseline to week 12 between barzolvolimab treatment and placebo of at least 9 points, using a common standard deviation of 14 points and a dropout rate not greater than 15%.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.7.1-2"></a>

###### Planned enrollment stated at the first dose, June 2022

> “Approximately 168 patients will be randomly assigned on a 1:1:1:1 ratio to receive subcutaneous injections of barzolvolimab at 75 mg every 4 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks or placebo during a 16-week placebo-controlled treatment phase.”

Source: [Celldex phase 2 CSU first patient dosed release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-first-patient-dosed-phase-2-study)

<a id="topic-3.1.4.7.1-3"></a>

###### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 208”

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-3.1.4.7.1-4"></a>

###### Participants screened, randomized, treated, and completing Week 12

> “From May 19, 2022, to June 15, 2023, a total of 350 patients were screened, of whom 208 were randomly assigned.”
> “There were 207 patients included in each of the mITT and safety populations.”
> “Overall, 189 patients (91.3%) completed 12 weeks of treatment (Fig 1)”
> “One patient was randomized but not treated.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.7.1-5"></a>

###### Participants per randomized group in the primary publication

> “randomized 1:1:1:1 to receive barzolvolimab 75 mg every 4 weeks (n = 53); 150 mg every 4 weeks (n = 52); 300 mg every 8 weeks (n = 51); or placebo (n = 51).”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.7.1-6"></a>

###### Participants treated and entering the 24-week follow-up period

> “Here we present the efficacy and safety of barzolvolimab during the 24-week follow up period”
> “208 patients enrolled and 207 patients treated”
> “189 patients entered the follow-up period”

Source: [Metz et al. (2025b)](https://celldex.com/wp-content/uploads/2025/06/EAACI_Congress_2025-Barzolvolimab-76-Week-LB-FINAL_6.13.25.pdf)

<a id="topic-3.1.4.7.1-7"></a>

###### Participants in the post hoc off-treatment analysis

> “We performed a post hoc analysis of efficacy in patients during the 24-week follow-up period who randomized to barzolvolimab 150 mg Q4W or 300 mg Q8W for 52 weeks (Arm 2 & 3), completed the full treatment period (52 weeks), achieved at least well-controlled disease (UAS7 ≤ 6) at Week 52 (n = 55) and had a reported UAS7 at Week 76 (n = 48)”
> “55/78 (71%) had UAS7 ≤ 6 (well controlled disease) at W52”

Source: [Metz et al. (2026b)](https://celldex.com/wp-content/uploads/2026/02/Barzol_AAAAI-CSU-OT-Analysis-2.27.26.pdf)

<a id="topic-3.1.4.7.1-8"></a>

###### Participants in the angioedema subgroup

> “A total of 149 (72%) patients had angioedema at baseline (AAS7>0)”

Source: [Metz et al. (2026c)](https://celldex.com/wp-content/uploads/2026/06/EAACI-2026-Angioedema-Flash-Talk-and-Slides.pdf)

<a id="topic-3.1.4.7.1-9"></a>

###### Participants in the pigmentation analysis

> “204 patients received ≥1 dose of barzolvolimab (any dose) and were included in this analysis”

Source: [Metz et al. (2026d)](https://celldex.com/wp-content/uploads/2026/10/FCD-2026_Pigmentation-Changes-Poster_FINAL.pdf)

<a id="topic-3.1.4.7.1-10"></a>

###### Participants in the baseline IgE subgroup analysis

> “Analysis was conducted in patients with observable data Weeks 12 and 52. Analysis included patients who received 150 mg or 300 mg of barzolvolimab for 52 weeks. Placebo comparison was done for the week 12 analysis.”

Source: [Metz et al. (2025e)](https://celldex.com/wp-content/uploads/2025/09/EADV2025_Poster.pdf)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Modified intent-to-treat and safety populations

> “The primary analysis was conducted when all patients completed week 12 of treatment.”
> “The modified intent-to-treat (mITT) population was all randomized patients who received at least one dose of study treatment and was analyzed according to the treatment group to which they were randomized.”
> “The safety population was all patients who received at least one dose of study treatment.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.7.2-2"></a>

###### Handling of missing daily diary scores

> “If a patient had at least 4 nonmissing daily UAS7 scores within the 7 days, the UAS7 score was calculated as the sum of the available diary UAS7 scores in that week, divided by the number of days that had a nonmissing diary UAS7 score, and multiplied by 7.”
> “If there were fewer than 4 nonmissing daily UAS7 scores, then the UAS7 score was considered to be missing.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.7.2-3"></a>

###### Week 12 primary analysis: analysis of covariance with multiple imputation and Benjamini-Hochberg adjustment

> “The primary comparison was the difference in means between the treatment groups versus placebo at week 12 using an analysis of covariance model with multiple imputation and was assessed by associated least squares (LS) mean differences, standard errors (SEs) and 95% confidence intervals (CIs) for comparing each treatment group vs placebo, and adjusted P values using the Benjamini-Hochberg procedure.”
> “Data for UAS7 well-controlled disease, complete response, and CSU-free status were analyzed in the mITT population by Cochran-Mantel-Haenszel tests for comparison between each active dosing regimen versus placebo.”
> “P values are nominal; only the primary end point P values were adjusted for multiplicity.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.7.2-4"></a>

###### Congress presentations: modified intent to treat and as-observed analyses

> “Modified intent to treat; observed data.”

Source: [Metz et al. (2025b)](https://celldex.com/wp-content/uploads/2025/06/EAACI_Congress_2025-Barzolvolimab-76-Week-LB-FINAL_6.13.25.pdf)

> “Modified intent to treat; observed data in subset of patients with positive AAS7 scores at baseline.”

Source: [Metz et al. (2025c)](https://celldex.com/wp-content/uploads/2025/06/EAACI-2025-Angioedema-Oral-Presentation-June-13-2025.pdf)

> “Analyses are as-observed.”

Source: [Metz et al. (2026c)](https://celldex.com/wp-content/uploads/2026/06/EAACI-2026-Angioedema-Flash-Talk-and-Slides.pdf)

<a id="topic-3.1.4.7.2-5"></a>

###### Pooled dose groups in the safety tables of the congress presentation

> “1 All dose levels (75mgQ4W, 150mgQ4W, 300mgQ8W) combined; 2 All dose levels combined; patients randomized to 75mgQ4W were re-randomized to 150mgQ4W or 300mgQ8W at week 16; 3 Patients received 36 weeks of barzolvolimab 150mgQ4W or 300mgQ8W after 16 weeks of placebo; data are shown for 36 week barzolvolimab experience”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

<a id="topic-3.1.4.7.2-6"></a>

###### Post hoc subgroup analyses by baseline IgE and baseline serum tryptase

> “Statistical analyses to determine significance between groups was conducted using one-way ANOVA with Tukey’s Multiple Comparisons Test, Welch's t-test, or z-test for two population proportions, as appropriate.”

Source: [Metz et al. (2025e)](https://celldex.com/wp-content/uploads/2025/09/EADV2025_Poster.pdf)

> “Exploratory, post hoc efficacy analyses from the Phase 2, double-blind, placebo-controlled study (NCT05368285) assessed the association of baseline serum tryptase with baseline disease severity and response to barzolvolimab at Week 12 and Week 52 in patients with H1-antihistamine-refractory CSU”
> “Receiver operating characteristic (ROC) analyses evaluated baseline serum tryptase as a predictor of treatment response”

Source: [Metz et al. (2026e)](https://celldex.com/wp-content/uploads/2026/11/ACAAI-2026-CSU-P2-High-Low-Tryptase-ePoster_R098.pdf)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Disposition through Week 12

> “There were 207 patients included in each of the mITT and safety populations.”
> “Overall, 189 patients (91.3%) completed 12 weeks of treatment (Fig 1)”
> “One patient was randomized but not treated.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.1-2"></a>

###### Treatment discontinuations through Week 52 by randomized group

| Reason | 75 mg every 4 weeks, then 150 or 300 mg | 150 mg every 4 weeks | 300 mg every 8 weeks | Placebo, then 150 or 300 mg |
| --- | --- | --- | --- | --- |
| Group size | “(n=53)” | “(n=52)” | “(n=52)” | “(n=51)” |
| Discontinued treatment, n (%) | “13 (25%)” | “13 (25%)” | “13 (25%)” | “8 (16%)” |
| Adverse event | “7 (13%)” | “4 (8%)” | “7 (13%)” | “2 (4%)” |
| Patient decision | “1 (2%)” | “3 (6%)” | “1 (2%)” | “3 (6%)” |
| Non-compliance | “2 (4%)” | “1 (2%)” | “1 (2%)” | “2 (4%)” |
| Lack of clinical response | “1 (2%)” | “0” | “2 (4%)” | “1 (2%)” |
| Other | “2 (4%)” | “5 (10%)” | “2 (4%)” | “0” |

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

> “Patient Disposition Through 52 Weeks”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

<a id="topic-3.1.4.8.1-3"></a>

###### Discontinuations during the 16-week placebo-controlled period and adverse events leading to discontinuation

> “Three patients discontinued placebo during the 16 week placebo-controlled period due to patient decision (2), non compliance (1)”
> “Adverse event discontinuations in more than one patient: hair color changes (6), urticaria (5), macrocytic anemia (2)”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

<a id="topic-3.1.4.8.1-4"></a>

###### Participants treated and entering the follow-up period

> “208 patients enrolled and 207 patients treated”
> “189 patients entered the follow-up period”

Source: [Metz et al. (2025b)](https://celldex.com/wp-content/uploads/2025/06/EAACI_Congress_2025-Barzolvolimab-76-Week-LB-FINAL_6.13.25.pdf)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Demographics and baseline disease characteristics by randomized group

| Characteristic | 75 mg every 4 weeks (n = 53) | 150 mg every 4 weeks (n = 52) | 300 mg every 8 weeks (n = 51) | Placebo (n = 51) |
| --- | --- | --- | --- | --- |
| Age (years), median (range) | “42.0 (18-69)” | “44.5 (21-81)” | “49.0 (20-80)” | “43.0 (20-76)” |
| Female sex, no. (%) | “40 (75.5)” | “39 (75.0)” | “41 (80.4)” | “36 (70.6)” |
| Weight (kg), mean (SD) | “77.49 (20.442)” | “80.86 (21.354)” | “85.73 (24.852)” | “83.81 (19.866)” |
| UAS7 score, mean (SD) | “30.30 (8.057)” | “30.75 (7.657)” | “31.33 (6.939)” | “30.09 (8.057)” |
| UAS7, severe disease (UAS7 ≥ 28), no. (%) | “34 (64.2%)” | “36 (69.2%)” | “39 (76.5%)” | “33 (64.7%)” |
| ISS7 score, mean (SD) | “15.44 (4.053)” | “15.70 (4.004)” | “16.42 (3.658)” | “15.61 (3.783)” |
| HSS7 score, mean (SD) | “14.86 (4.588)” | “15.05 (5.045)” | “14.92 (4.387)” | “14.47 (4.842)” |
| UCT score, mean (SD) | “3.67 (2.826)” | “3.67 (2.503)” | “2.96 (2.630)” | “3.38 (2.472)” |
| Angioedema at baseline (AAS7 > 0), no. (%) | “40 (75.5%)” | “35 (67.3%)” | “42 (82.4%)” | “32 (62.7%)” |
| Duration of CSU (years), mean (SD) | “5.44 (5.352)” | “5.47 (6.538)” | “6.28 (6.554)” | “5.27 (6.565)” |
| Previous experience with omalizumab, no. (%) | “11 (20.8)” | “11 (21.2)” | “11 (21.6)” | “8 (15.7)” |
| Baseline IgE (IU/mL), median (IQR) | “81 (27.0-271.0)” | “60 (13.0-135.0)” | “91.5 (35.5-218.0)” | “101.5 (25.0-237.8)” |
| Dermatology Life Quality Index, mean (SD) | “15.88 (7.596)” | “15.65 (7.634)” | “17.37 (7.534)” | “16.98 (6.556)” |
| Baseline tryptase (ng/mL), median (IQR) | “5.25 (3.43-6.80)” | “5.40 (4.30-6.90)” | “4.80 (3.85-6.55)” | “4.40 (3.25-6.55)” |

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.2-2"></a>

###### Baseline imbalances in the 300 mg every 8 weeks group

> “In the 300 mg barzolvolimab group at baseline, there were more patients with higher body weights, more patients with severe CSU (UAS7 ≥ 28), and a higher percentage of patients with angioedema (82%) than the lower-dose groups of barzolvolimab and the placebo group.”
> “Overall, the patient population in this study had severe CSU measured by UAS7 (≥28), Urticaria Control Test score (<6), high rate of angioedema (>60%), and long duration of CSU (>5 years).”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.2-3"></a>

###### Prior omalizumab and omalizumab-refractory disease

> “Approximately 20% (n=41) of enrolled patients received prior treatment with omalizumab and more than half of these patients had omalizumab-refractory disease.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.4.8.2-4"></a>

###### Baseline AAS7 in participants with angioedema at baseline

> “In patients with angioedema at baseline, mean AAS7 at baseline ranged from 53 to 56 points, indicating that patients presented with severe angioedema symptoms prior to treatment”
> “Patients with angioedema had numerically longer disease duration and worse quality of life (as measured by Dermatology Quality of Life Index [DLQI]) vs patients without angioedema at baseline”

Source: [Metz et al. (2026c)](https://celldex.com/wp-content/uploads/2026/06/EAACI-2026-Angioedema-Flash-Talk-and-Slides.pdf)

<a id="topic-3.1.4.8.2-5"></a>

###### Baseline UCT and DLQI in the 150 mg and 300 mg groups

> “Baseline mean (SD) UCT scores were 3.7 (2.5) and 3.0 (2.6) in the 150mg Q4W and 300mg Q8W groups, respectively, indicating poorly controlled urticaria.”
> “Baseline mean (SD) DLQI was 15.7 (7.6) and 17.4 (7.5) in the 150mg Q4W and 300mg Q8W groups, respectively, indicating a very large impact of disease on QoL.”

Source: [Maurer et al. (2025a)](https://doi.org/10.1016/j.jaci.2024.12.985)

<a id="topic-3.1.4.8.2-6"></a>

###### Baseline characteristics of participants with well-controlled disease at Week 52

> “Patients With Well Controlled Disease at Week 52”
> “66.7% and 68.9% of patients had severe CSU and angioedema, respectively, at baseline”

Source: [Metz et al. (2026b)](https://celldex.com/wp-content/uploads/2026/02/Barzol_AAAAI-CSU-OT-Analysis-2.27.26.pdf)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Week 12 primary endpoint: UAS7 change from baseline versus placebo

> “There was significant improvement in mean (95% confidence interval) change from baseline to week 12 in UAS7 in barzolvolimab-treated patients compared to patients who received placebo (75 mg every 4 weeks: -6.60 [-10.71, -2.49] P = .0017; 150 mg every 4 weeks: -12.55 [-16.56, -8.55] P < .0001; 300 mg every 8 weeks: -13.41 [-17.47, -9.34] P < .0001).”
> “Barzolvolimab demonstrated a rapid (within 2 weeks) and marked improvement in UAS7 scores through week 12 (Fig 2, B).”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.3-2"></a>

###### Week 12 efficacy endpoints by randomized group

| Endpoint at Week 12 | 75 mg every 4 weeks (n = 53) | 150 mg every 4 weeks (n = 52) | 300 mg every 8 weeks (n = 51) | Placebo (n = 51) |
| --- | --- | --- | --- | --- |
| UAS7 LS mean change from baseline (SE) | “−17.06 (1.493)” | “−23.02 (1.416)” | “−23.87 (1.479)” | “−10.47 (1.462)” |
| UAS7 treatment difference vs placebo (95% CI) | “−6.60 (−10.71, −2.49)” | “−12.55 (−16.56, −8.55)” | “−13.41 (−17.47, −9.34)” | Not applicable |
| ISS7 LS mean change from baseline (SE) | “−8.62 (0.794)” | “−11.68 (0.766)” | “−11.79 (0.788)” | “−5.47 (0.784)” |
| ISS7 treatment difference vs placebo (95% CI) | “−3.16 (−5.41, −0.91)” | “−6.21 (−8.38, −4.04)” | “−6.32 (−8.50, −4.13)” | Not applicable |
| HSS7 LS mean change from baseline (SE) | “−8.25 (0.747)” | “−11.19 (0.750)” | “−12.19 (0.745)” | “−4.95 (0.772)” |
| HSS7 treatment difference vs placebo (95% CI) | “−3.31 (−5.40, −1.22)” | “−6.24 (−8.33, −4.16)” | “−7.24 (−9.36, −5.12)” | Not applicable |
| AAS7 LS mean change from baseline (SE) | “−24.10 (2.831)” | “−27.99 (2.815)” | “−29.95 (2.843)” | “−12.56 (3.056)” |
| AAS7 treatment difference vs placebo (95% CI) | “−11.55 (−20.04, −3.05)” | “−15.43 (−23.52, −7.34)” | “−17.39 (−25.49, −9.30)” | Not applicable |
| Well-controlled disease (UAS7 ≤ 6) (%) | “41.7” | “59.6” | “62.5” | “12.8” |
| UAS7 ≤ 6 difference in proportions vs placebo (95% CI) | “0.29 (0.12, 0.46)” | “0.47 (0.3, 0.64)” | “0.50 (0.33, 0.66)” | Not applicable |
| Complete control (UAS7 = 0) (%) | “22.9” | “51.1” | “37.5” | “6.4” |
| UAS7 = 0 difference in proportions vs placebo (95% CI) | “0.17 (0.03, 0.3)” | “0.45 (0.29, 0.61)” | “0.31 (0.16, 0.46)” | Not applicable |
| CSU-free status (ISS7 = 0, HSS7 = 0, and AAS7 = 0) (%) | “19.2” | “50.0” | “33.3” | “5.9” |

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.3-3"></a>

###### Week 12 complete response (UAS7 = 0) and well-controlled disease (UAS7 ≤ 6) versus placebo

> “UAS7 responses to barzolvolimab were greater for all doses versus placebo: 41.7% of 75 mg every 4 weeks, 59.6% of 150 mg every 4 weeks, and 62.5% of 300 mg every 8 weeks barzolvolimab-treated patients had well-controlled disease (UAS7 ≤ 6) at week 12 compared to 12.8% of patients who received placebo (Fig 2, C, P < .01 for all comparisons with placebo; Table II).”
> “Similarly, 22.9% of 75 mg every 4 weeks, 51.1% of 150 mg every 4 weeks, and 37.5% of 300 mg every 8 weeks barzolvolimab-treated patients experienced complete response (UAS7 = 0) at week 12 compared to 6.4% of patients who received placebo (Fig 2, D, P < .05 for all comparisons with placebo; Table II).”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.3-4"></a>

###### Week 12 UAS7 change by prior omalizumab treatment

> “Patients with prior omalizumab treatment also demonstrated benefits on LS mean change from baseline in UAS7 at week 12 (nominal P = .0322, P = .0236, and P = .005 for the 75 mg every 4 weeks, 150 mg every 4 weeks and 300 mg every 8 weeks barzolvolimab groups, respectively) that were numerically similar to benefits in omalizumab-naïve patients and the overall population; similar trends were observed in patients in the omalizumab-refractory subgroup, although the number of patients in this subgroup was small (Fig 3).”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.3-5"></a>

###### Week 12 angioedema activity (AAS7) in participants with angioedema at baseline

> “Barzolvolimab treatment also resulted in rapid (within 1 week) and durable symptom improvement for patients with angioedema at baseline in AAS7 change from baseline through week 12 compared to patients who received placebo (Fig 4 and Table II; nominal P < .01 for all barzolvolimab doses vs placebo).”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.3-6"></a>

###### Week 12 AAS7 improvement of more than 8 points and angioedema-free days

| Measure at Week 12 (participants with angioedema at baseline) | 300 mg every 8 weeks | 150 mg every 4 weeks | 75 mg every 4 weeks | Placebo |
| --- | --- | --- | --- | --- |
| Angioedema at baseline, n (%) | “42 (82%)” | “35 (67%)” | “40 (75%)” | “32 (63%)” |
| Baseline AAS7 (mean) | “53.15” | “54.60” | “54.05” | “56.30” |
| >8 point improvement in AAS7 (%) | “85.0” | “87.1” | “82.9” | “57.1” |
| Angioedema free days (mean) | “65.1” | “54.5” | “43.3” | “36.2” |

Source: [Celldex phase 2 CSU angioedema release (2024)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-data-demonstrating-profound)

> “AAS7 data were analyzed using ANCOVA model and multiple imputation. Data are presented for patients with angioedema at baseline.”
> “Barzolvolimab increased angioedema free days compared to placebo through 12 weeks. Patients in the 300 mg cohort were angioedema free 77% of the time over the 12 week period.”

Source: [Celldex phase 2 CSU angioedema release (2024)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-data-demonstrating-profound)

<a id="topic-3.1.4.8.3-7"></a>

###### Week 12 serum tryptase reduction

> “Reductions in serum tryptase, a correlate of MC load,”
> “were apparent in patients treated with barzolvolimab, but not with placebo, and were numerically greater for the 150 mg every 4 weeks and 300 mg every 8 weeks treatment groups, than for the 75 mg every 4 weeks treatment group.”
> “Serum tryptase at baseline and week 12 in indicated subgroups.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.3-8"></a>

###### Week 52 complete response (UAS7 = 0) and well-controlled disease (UAS7 ≤ 6) after re-randomization at Week 16

| Group | UAS7 ≤ 6 at Week 12 (%) | UAS7 ≤ 6 at Week 52 (%) | UAS7 = 0 at Week 12 (%) | UAS7 = 0 at Week 52 (%) |
| --- | --- | --- | --- | --- |
| 75 mg every 4 weeks, then 150 or 300 mg | “41.7” | “67.4” | “22.9” | “53.5” |
| 150 mg every 4 weeks | “59.6” | “73.7” | “51.1” | “71.1” |
| 300 mg every 8 weeks | “62.5” | “68.2” | “37.5” | “52.3” |
| Placebo, then 150 or 300 mg | “12.8” | “63.0” | “6.4” | “58.7” |

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

> “Placebo and 75mg Q4W re-randomized to 150mg Q4W or 300mg Q8W at Week 16”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

<a id="topic-3.1.4.8.3-9"></a>

###### Week 52 response stated by the company and by prior omalizumab experience

> “71% of patients treated with barzolvolimab 150 mg Q4W and 52% of patients treated with 300 mg Q8W had a complete response (no itch/hives; UAS7=0) at Week 52. These responses were observed early and sustained through 52 weeks.”
> “At Week 16, patients receiving low dose barzolvolimab (75 mg) or placebo were transitioned to barzolvolimab 150 mg or 300 mg; after crossover, these patients experienced similar clinically meaningful disease response as the rest of the study population.”
> “These robust responses were observed regardless of prior omalizumab experience.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.4.8.3-10"></a>

###### Week 52 angioedema activity (AAS7) in participants with angioedema at baseline

> “Barzolvolimab improvement from baseline: 86% reduction for 150 mg Q4W and 82% reduction for 300 mg Q8W at Week 52”
> “Patients who received 150 mg Q4W and 300 mg Q8W were angioedema free 72% and 70% of the time over the 52-week period.”
> “Placebo treated patients had 33% of angioedema free days through Week 12.”
> “Up to 87% of patients reported clinically meaningful improvement (≥8 point) in AAS7 at Week 52”
> “Up to 77% of patients who had angioedema at baseline were angioedema free at Week 52”

Source: [Metz et al. (2025c)](https://celldex.com/wp-content/uploads/2025/06/EAACI-2025-Angioedema-Oral-Presentation-June-13-2025.pdf)

<a id="topic-3.1.4.8.3-11"></a>

###### Week 52 and Week 76 AAS7 change and angioedema-free status (AAS7 = 0) across the four groups

> “At week 52, the mean change from baseline was similar across the 4 treatment groups, ranging from -39.82 to -47.75”
> “At 28 weeks after their last dose, the mean change across treatment groups ranged from -31.52 to -43.11”
> “At week 52, between 67% and 77% of patients with angioedema at baseline across the 4 treatment groups reached AAS7=0”
> “At 28 weeks after their last dose, between 52% to 64% of patients across the 4 treatment groups were angioedema-free”

Source: [Metz et al. (2026c)](https://celldex.com/wp-content/uploads/2026/06/EAACI-2026-Angioedema-Flash-Talk-and-Slides.pdf)

<a id="topic-3.1.4.8.3-12"></a>

###### Week 12 and Week 52 efficacy by baseline IgE

> “Changes in UAS7 or UCT7 at Weeks 12 and 52”
> “Patients receiving placebo, or barzolvolimab at 150 mg Q4W or 300 mg Q8W were subgrouped according to baseline IgE levels as previously defined”
> “Similarly strong efficacy was observed in patients with normal/high (≥ 40 IU/mL) or low (< 40 IU/mL) IgE levels for both dosing regimens as determined by:”
> “Adjusted p-value was non-significant for all comparisons between normal/high vs IgE low subgroups in indicated analyses.”
> “The rate ratio (95% CI) of achieving a complete response in patients with low compared to normal/high baseline IgE was 1.37 (0.74-2.55) and 1.24 (0.71-2.16) in the 150 mg Q4W and 300 mg Q8W groups, respectively.”

Source: [Metz et al. (2025e)](https://celldex.com/wp-content/uploads/2025/09/EADV2025_Poster.pdf)

<a id="topic-3.1.4.8.3-13"></a>

###### Week 12 and Week 52 efficacy by baseline serum tryptase

> “Baseline serum tryptase is not predictive of barzolvolimab response at Week 12 or Week 52”
> “ROC analysis showed no predictive value of baseline serum tryptase for response (AUC ≤0.56)”
> “Baseline serum tryptase was not associated with baseline disease severity nor was predictive of barzolvolimab response”

Source: [Metz et al. (2026e)](https://celldex.com/wp-content/uploads/2026/11/ACAAI-2026-CSU-P2-High-Low-Tryptase-ePoster_R098.pdf)

<a id="topic-3.1.4.8.3-14"></a>

###### Week 76, 28 weeks after the last dose: UAS7 change, UAS7 = 0, and UAS7 ≤ 6

> “In this Phase 2 trial (n=208) of barzolvolimab in patients with antihistamine-refractory CSU, sustained treatment benefits were observed over 28 weeks after the last dose”
> “UAS7 Mean CFB (SE) at W76”
> “150 mg Q4W was -20.4 (2.5)”
> “300 mg Q8W was -21.1 (1.9)”
> “UAS7=0 (%) at W76”
> “150 mg Q4W was 41%”
> “300 mg Q8W was 35%”
> “UAS7≤6 (%) at W76”
> “150 mg Q4W was 56%”
> “300 mg Q8W was 47%”
> “Modified intent to treat; observed data.”

Source: [Metz et al. (2025b)](https://celldex.com/wp-content/uploads/2025/06/EAACI_Congress_2025-Barzolvolimab-76-Week-LB-FINAL_6.13.25.pdf)

<a id="topic-3.1.4.8.3-15"></a>

###### Week 76 UAS7 change stated by the company

> “UAS7 mean change from baseline at Week 76 was -20.42 for patients treated with 150 mg Q4W and -21.10 for patients treated with 300 mg Q8W.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.4.8.3-16"></a>

###### Week 76 in participants with well-controlled disease (UAS7 ≤ 6) at Week 52

> “In a Phase 2 trial of patients with antihistamine-refractory CSU treated with barzolvolimab (150 mg Q4W or 300 mg Q8W for 1 year), 71% had well controlled disease at the end of the treatment period”
> “Of those with at least well controlled disease, 88% had a complete response (UAS7 = 0)”
> “69% of patients who achieved well controlled disease after 52 weeks of treatment, also achieved well controlled disease at week 76”
> “50% of patients who achieved well controlled disease after 52 weeks of treatment, achieved complete response at week 76”
> “Concentration of barzolvolimab falls below therapeutic levels by week 64”
> “Tryptase recovers towards range of healthy subjects by week 76 indicating normal mast cell numbers”

Source: [Metz et al. (2026b)](https://celldex.com/wp-content/uploads/2026/02/Barzol_AAAAI-CSU-OT-Analysis-2.27.26.pdf)

<a id="topic-3.1.4.8.3-17"></a>

###### Week 76 disease severity at recurrence after treatment completion

> “For patients who did experience recurrence of disease symptoms after treatment completion, their disease was much milder than what it was at baseline.”
> “83% reported no impact of disease on QoL (DLQI 0/1) at Week 76 and 74% of patients with angioedema at baseline were angioedema free (AAS7=0)”

Source: [Celldex AAAAI 2026 data release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-presents-additional-positive-data-phase-2-chronic)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.4.8.4-1"></a>

###### Week 12 Urticaria Control Test (UCT7): treatment differences versus placebo

> “At baseline, mean UCT7 scores ranged from 3.8-5.5, indicating poor disease control.”
> “Treatment with barzolvolimab led to markedly improved disease control, with least squares mean (95% CI) treatment differences in change from baseline UCT7 at 12W of 5.8 (4.2, 7.5) and 4.8 (3.1, 6.5) for 150mg Q4W and 300mg Q8W, respectively (both p<0.0001).”
> “Over 89% of patients achieved a clinically meaningful benefit in UCT7 at 12W.”

Source: [Metz et al. (2025f)](https://www.annallergy.org/article/S1081-1206%2825%2900523-X/fulltext)

<a id="topic-3.1.4.8.4-2"></a>

###### Well-controlled urticaria (UCT7 ≥ 12) at 12 and 52 weeks and 28 weeks after the last dose

> “At least well-controlled urticaria (UCT7≥12) was achieved in 68.1% and 61.7% (12 weeks) and 85.7% and 71.4% (52 weeks) for the 150mg Q4W and 300mg Q8W doses, respectively.”
> “Well-controlled urticaria was still present at 28 weeks following the last dose of barzolvolimab in 59.4% and 53.6% of patients, respectively.”

Source: [Metz et al. (2025f)](https://www.annallergy.org/article/S1081-1206%2825%2900523-X/fulltext)

<a id="topic-3.1.4.8.4-3"></a>

###### Week 12 DLQI 0 or 1 and UCT ≥ 12

> “These data are from the 12 week analysis. 67% and 57% of patients treated with 150 mg Q4W or 300 mg Q8W, respectively, reported improvement of CSU and their quality of life (DLQI score of 0 or 1). The majority of patients (>65%) treated with 150 mg Q4W or 300 mg Q8W achieved well-controlled urticaria (UCT≥12).”

Source: [Celldex phase 2 CSU 52-week results release (2024)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-landmark-52-week-results)

<a id="topic-3.1.4.8.4-4"></a>

###### Week 52 UCT and DLQI change from baseline in the 150 mg and 300 mg groups

> “Baseline mean (SD) UCT scores were 3.7 (2.5) and 3.0 (2.6) in the 150mg Q4W and 300mg Q8W groups, respectively, indicating poorly controlled urticaria.”
> “Treatment demonstrated marked improvement in UCT, with mean (SD) change from baseline (CFB) at 52 weeks 10.5 (3.9) and 9.4 (5.0), respectively.”
> “Baseline mean (SD) DLQI was 15.7 (7.6) and 17.4 (7.5) in the 150mg Q4W and 300mg Q8W groups, respectively, indicating a very large impact of disease on QoL.”
> “At 52 weeks, the mean CFB in DLQI was -14.2 (7.3) and -15.0 (8.5), respectively.”

Source: [Maurer et al. (2025a)](https://doi.org/10.1016/j.jaci.2024.12.985)

<a id="topic-3.1.4.8.4-5"></a>

###### Week 52 DLQI 0 or 1, DLQI improvement, and UCT control stated by the company

> “Up to 82% of patients reported that CSU symptoms no longer had an impact on their quality of life at Week 52 and up to 95% of patients reported meaningful improvement in quality of life based on DLQI at Week 52.”
> “Up to 82% of patients reported well-controlled urticaria based on UCT, and approximately half of patients reported complete control at Week 52.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.4.8.4-6"></a>

###### Week 76 DLQI 0 or 1

> “DLQI 0 or 1 at W76”
> “150 mg Q4W was 48%”
> “300 mg Q8W was 40%”
> “Modified intent to treat; observed data.”

Source: [Metz et al. (2025b)](https://celldex.com/wp-content/uploads/2025/06/EAACI_Congress_2025-Barzolvolimab-76-Week-LB-FINAL_6.13.25.pdf)

<a id="topic-3.1.4.8.4-7"></a>

###### Week 76 DLQI in participants with well-controlled disease (UAS7 ≤ 6) at Week 52

> “The mean (SE) DLQI at W76 for patients with well controlled disease at week 52 was 1.2 (0.75)”
> “20/24 (83%) reported a DLQI 0/1 (no impact of disease on QoL) at week 76”

Source: [Metz et al. (2026b)](https://celldex.com/wp-content/uploads/2026/02/Barzol_AAAAI-CSU-OT-Analysis-2.27.26.pdf)

<a id="topic-3.1.4.8.4-8"></a>

###### Week 52 and Week 76 DLQI in the post hoc quality of life analysis

> “In the post hoc analysis presented at AAD, the impact of disease on QoL for the subset of patients who received 52 weeks of barzolvolimab therapy (150 mg Q4W or 300 mg Q8W) and completed treatment with at least well controlled disease (UAS7<6) at Week 52 and had DLQI data through Week 76 was explored.”
> “At Week 52, 94% of patients with well controlled disease at Week 52 also had a DLQI of 0/1, indicating their disease had no impact on their QoL .”
> “76% of patients with well controlled disease at Week 52 also reported that the disease had small to no impact (DLQI score ≤ 5) on their QoL at Week 76.”
> “Profound improvements were observed across all 6 domains at both Weeks 52 and 76.”

Source: [Celldex AAD 2026 quality of life release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-presents-positive-data-phase-2-chronic-spontaneous)

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Baseline through Week 12: adverse events, serious adverse events, and discontinuations

> “Safety and tolerability of barzolvolimab were assessed by the proportion of patients reporting treatment-emergent adverse events (TEAEs) and serious AEs, and TEAEs leading to treatment discontinuation from baseline through week 12.”
> “Overall, 88 barzolvolimab-treated patients (56.4%) and 14 patients who received placebo (27.5%) reported a TEAE.”
> “In the 300 mg every 8 weeks group, one barzolvolimab-treated patient (2.0%) experienced a serious AE of external ear canal cholesteatoma that was considered unrelated to treatment and resolved during the study.”
> “A total of 7 barzolvolimab-treated patients (4.5%) experienced a TEAE that led to study treatment discontinuation; this included neutropenia (n = 2), abdominal pain (n = 1), hair color change (n = 3), dizziness (n = 1), urticaria (n = 1), and thrombocytopenia (n = 1).”
> “None of the patients who received placebo had a TEAE that led to study treatment discontinuation. There were no deaths during the study.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

| Event | 75 mg every 4 weeks (n = 53) | 150 mg every 4 weeks (n = 52) | 300 mg every 8 weeks (n = 51) | Pooled barzolvolimab (n = 156) | Placebo (n = 51) |
| --- | --- | --- | --- | --- | --- |
| Patients with ≥1 TEAE | “28 (52.8)” | “29 (55.8)” | “31 (60.8)” | “88 (56.4)” | “14 (27.5)” |
| Patients with serious AE | “0” | “0” | “1 (2.0)” | “1 (0.6)” | “0” |
| Discontinued study treatment due to TEAE | “2 (3.8)” | “1 (1.9)” | “4 (7.8)” | “7 (4.5)” | “0” |
| Hair color changes | “0” | “5 (9.6)” | “9 (17.6)” | “14 (9.0)” | “0” |
| Urticaria/CSU | “8 (15.1)” | “5 (9.6)” | “3 (5.9)” | “16 (10.3)” | “5 (9.8)” |
| Neutropenia (neutropenia and neutrophil count decreased) | “4 (7.6)” | “3 (5.7)” | “5 (9.8)” | “12 (7.7)” | “0” |

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.5-2"></a>

###### Week 12 neutropenia: onset, duration, and infections

> “Similar to other AEs, most events of neutropenia/decreased neutrophil count were of mild to moderate intensity; the onset typically occurred within 1 to 3 months and lasted 3 to 4 weeks while receiving treatment.”
> “Although neutropenia was observed in 7.7% of barzolvolimab-treated patients, it was not associated with infections.”
> “Analysis of hematology laboratory parameters showed a 1.65 × 109/L mean decrease in neutrophils in the barzolvolimab-treated patients between baseline and week 12”
> “There was one patient in the 75 mg barzolvolimab group with two consecutive neutrophil counts in the grade 3 range”
> “and this patient was discontinued, as per the study’s protocol.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.5-3"></a>

###### Week 12 adverse events stated by the company

> “Most adverse events were mild to moderate in severity; through 12 weeks, the most common treatment emergent adverse events in barzolvolimab treated patients were urticaria/CSU (10%), hair color changes (9%), and neutropenia/ANC decrease (8%). The rate of infections was similar between barzolvolimab treated patients and placebo with no association between neutropenia and infections.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.4.8.5-4"></a>

###### Week 16 placebo-controlled period and Week 52 full treatment period: adverse events

| Patients, n (%) | Barzolvolimab, all doses, Weeks 0 to 16 (N= 156) | Placebo, Weeks 0 to 16 (N= 51) | Barzolvolimab, all doses, Weeks 0 to 52 (N= 156) | Placebo then barzolvolimab, 36 weeks (N=48) |
| --- | --- | --- | --- | --- |
| At least one AE | “103 (66)” | “20 (39)” | “139 (89)” | “32 (67)” |
| Treatment related SAEs | “0” | “0” | “2 (1)” | “0” |
| Hair color changes | “22 (14)” | “0” | “40 (26)” | “8 (17)” |
| Neutropenia / neutrophil count decreased | “14 (9)” | “0” | “26 (17)” | “2 (4)” |
| Urticaria | “15 (10)” | “5 (10)” | “23 (15)” | “3 (6)” |
| Skin hypopigmentation | “2 (1)” | “0” | “21 (13)” | “9 (19)” |
| Nasopharyngitis | “6 (4)” | “3 (6)” | “15 (10)” | “4 (8)” |

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

> “Placebo Controlled Period (16 weeks)”
> “Full Treatment Period (52 weeks)”
> “4 SAEs of worsening urticaria symptoms”
> “Most events were grade 1 (mild), mechanism-related (KIT) and expected to be reversible”
> “Adverse events were not dose dependent”
> “No association between infections and neutropenia/decreased neutrophil counts”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

<a id="topic-3.1.4.8.5-5"></a>

###### Week 52 neutrophil counts and skin hypopigmentation stated by the company

> “Barzolvolimab was well tolerated with a favorable safety profile through 52 weeks of treatment.”
> “Neutrophil counts did not decline further with continued dosing and there was no association between infections and neutropenia. The hypopigmentation was observed with longer term exposure and did not lead to treatment discontinuation.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.4.8.5-6"></a>

###### Follow-up period through 76 weeks: neutrophil recovery and reversibility of pigment changes

> “Barzolvolimab was well tolerated with no new safety findings identified during follow up period”
> “Neutropenia/neutrophil count events resolved while on treatment and were not associated with infection”
> “Resolution of hair color changes and skin hypopigmentation observed following discontinuation of treatment”

Source: [Metz et al. (2025b)](https://celldex.com/wp-content/uploads/2025/06/EAACI_Congress_2025-Barzolvolimab-76-Week-LB-FINAL_6.13.25.pdf)

> “Barzolvolimab was well tolerated with a favorable safety profile through 76 weeks. No new safety signals were identified during the follow-up period. As expected, neutrophil counts returned to baseline following the completion of barzolvolimab treatment and the mild hair color changes and skin hypopigmentation observed on study were demonstrated to be reversible following discontinuation of treatment.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.4.8.5-7"></a>

###### Hair color and skin pigmentation changes over 76 weeks: incidence, onset, severity, and resolution

> “The objective of this analysis was to assess the rate and reversibility of pigmentation changes over 76 weeks in patients with CSU treated with barzolvolimab”
> “Hair color changes (hypopigmentation) occurred in 49 (24%) patients; 96% of hair color changes were mild (Grade 1). Mean time to onset was ≈4 months, with 91% of evaluable patients reporting resolution of hair color change by the end of study participation”
> “Skin hypopigmentation occurred in 36 (18%) patients and events were mostly mild (94%; Grade 1); mean onset was ≈9 months, with 68% of evaluable patients reporting resolution by data cutoff”
> “Skin hyperpigmentation occurred in 6 (3%) patients, all of whom reported the events as mild (Grade 1); mean time to onset was ≈5 months, with 67% of evaluable patients reporting resolution by data cutoff (photographs not available)”
> “Discontinuation due to pigmentation changes was low (hair color changes: 3%, n=6; skin hypopigmentation, n=0; skin hyperpigmentation: <0.5%, n=1 )”

Source: [Metz et al. (2026d)](https://celldex.com/wp-content/uploads/2026/10/FCD-2026_Pigmentation-Changes-Poster_FINAL.pdf)

<a id="topic-3.1.4.8.5-8"></a>

###### Limitations of the pigmentation photography stated by the authors

> “There were no protocol-defined standardization procedures for photography of hair or skin pigmentation changes”
> “Images were obtained from a subset of patients and may not be representative of all events observed in the trial.”

Source: [Metz et al. (2026d)](https://celldex.com/wp-content/uploads/2026/10/FCD-2026_Pigmentation-Changes-Poster_FINAL.pdf)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

- Sample size: the study was sized at 168 participants (42 per group) for 80% power to detect a UAS7 difference of at least 9 points at week 12. Of 208 participants randomized, 207 were in the mITT and safety populations. Approximately 20% (n=41) had prior omalizumab, and the authors state of the omalizumab-refractory subgroup that “the number of patients in this subgroup was small”.
- Duration of placebo control: the placebo-controlled treatment phase ran from baseline to week 16. At Week 16 the placebo and 75 mg groups were re-randomized 1:1 to 150 mg Q4W or 300 mg Q8W for 36 weeks, so every group received barzolvolimab from Week 16 to Week 52.
- Peer-reviewed scope: the primary publication reports the primary analysis, conducted when all participants completed week 12. Week 52 results are from a congress presentation based on an interim data cut of July 31, 2024, and Week 76 results are from congress presentations and the Form 10-Q.
- Multiplicity: the publication states “P values are nominal; only the primary end point P values were adjusted for multiplicity.”
- Missing data: the week 12 primary analysis used analysis of covariance with multiple imputation, while the Week 76 and angioedema congress analyses are labeled modified intent to treat with observed data or as-observed. Overall, 189 participants (91.3%) completed 12 weeks of treatment. Through 52 weeks, 13 (25%) participants in each of the three barzolvolimab groups and 8 (16%) in the placebo-then-barzolvolimab group discontinued treatment, including 7 (13%), 4 (8%), 7 (13%), and 2 (4%) for adverse events.
- Off-treatment and post hoc analyses: the last dose was at Week 48, followed by a 24-week off-treatment follow-up from Week 52 to Week 76. The off-treatment efficacy analysis was post hoc and limited to participants randomized to 150 mg Q4W or 300 mg Q8W who completed 52 weeks with UAS7 ≤ 6 at Week 52 (n = 55), of whom 48 had a reported UAS7 at Week 76. The baseline serum tryptase analyses were exploratory and post hoc.
- Baseline imbalance: the 300 mg group had more participants with higher body weights, more with severe CSU (UAS7 ≥ 28), and a higher percentage with angioedema (82%) than the lower-dose groups and the placebo group.
- Regimens: the phase 2 groups received 150 mg every 4 weeks or 300 mg every 8 weeks for 52 weeks, with placebo injections at the intervening visits of the every-8-weeks group; the phase 3 regimens follow a 300 mg or 450 mg loading dose.
- Counts that differ across documents: the study is described as conducted across 9 countries (Form 10-Q), at ~75 sites in 10 countries (52-week presentation), and at 56 locations (registry); the 300 mg every 8 weeks group is n = 51 in the primary publication and n=52 in the 52-week presentation.
- Immunogenicity: no antidrug antibody results from this study were found.
- Pigmentation analysis: the authors state “There were no protocol-defined standardization procedures for photography of hair or skin pigmentation changes” and that images were obtained from a subset of participants.

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018); [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285); [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm); [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf); [Metz et al. (2025b)](https://celldex.com/wp-content/uploads/2025/06/EAACI_Congress_2025-Barzolvolimab-76-Week-LB-FINAL_6.13.25.pdf); [Metz et al. (2025c)](https://celldex.com/wp-content/uploads/2025/06/EAACI-2025-Angioedema-Oral-Presentation-June-13-2025.pdf); [Metz et al. (2026b)](https://celldex.com/wp-content/uploads/2026/02/Barzol_AAAAI-CSU-OT-Analysis-2.27.26.pdf); [Metz et al. (2026c)](https://celldex.com/wp-content/uploads/2026/06/EAACI-2026-Angioedema-Flash-Talk-and-Slides.pdf); [Metz et al. (2026d)](https://celldex.com/wp-content/uploads/2026/10/FCD-2026_Pigmentation-Changes-Poster_FINAL.pdf); [Metz et al. (2026e)](https://celldex.com/wp-content/uploads/2026/11/ACAAI-2026-CSU-P2-High-Low-Tryptase-ePoster_R098.pdf); [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="heading-3.1.5"></a>

#### 3.1.5 CDX0159-02

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Primary objective: safety of multiple doses

> “The main objective of the trial was to evaluate the barzolvolimab MAD safety profile.”
> “Primary and secondary objectives were safety and disease activity (UAS7 and urticaria control test [UCT]).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

> “This is a study to determine the safety of multiple doses of CDX-0159 in patients with Chronic Spontaneous Urticaria.”

Source: [ClinicalTrials.gov NCT04538794](https://clinicaltrials.gov/study/NCT04538794)

<a id="topic-3.1.5.1-2"></a>

###### Secondary objectives: pharmacokinetics, disease activity, tryptase, SCF, and immunogenicity

> “The secondary objectives were to characterize the barzolvolimab MAD PK profile; PD effect (UAS7, HSS7, itch severity score [ISS7], and urticaria control test [UCT]); tryptase and SCF levels; and immunogenicity.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.1-3"></a>

###### Registry purpose: safety, pharmacodynamics, and pharmacokinetics in antihistamine-refractory CSU

> “The purpose of the study is to explore the safety, pharmacodynamics, and pharmacokinetics of ascending doses of CDX-0159 in patients with Chronic Spontaneous Urticaria who remain symptomatic despite treatment with antihistamines.”

Source: [ClinicalTrials.gov NCT04538794](https://clinicaltrials.gov/study/NCT04538794)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Registry dates and study sites in the United States and Germany

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2020-09-24” |
| Primary completion (actual) | “2023-01-17” |
| Study completion (actual) | “2023-01-17” |
| Countries of listed sites | “United States”; “Germany” |
| Site in Germany | “Charite University” |

Source: [ClinicalTrials.gov NCT04538794](https://clinicaltrials.gov/study/NCT04538794)

<a id="topic-3.1.5.2-2"></a>

###### Multicenter study

> “We have completed a Phase 1b randomized, double-blind, placebo-controlled multi-center study of barzolvolimab in CSU.”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="topic-3.1.5.2-3"></a>

###### First participant dosed, October 2020

> “HAMPTON, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened and the first patient has been dosed in its randomized, double-blind Phase 1b study of CDX-0159 in patients with chronic spontaneous urticaria (CSU).”

Source: [Celldex phase 1b CSU initiation release (2020)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-initiates-phase-1b-study-cdx-0159-chronic)

<a id="topic-3.1.5.2-4"></a>

###### Study completion reported in June 2023

> “HAMPTON, N.J., June 10, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that updated data from the Company’s Phase 1b multi-dose clinical trial in chronic spontaneous urticaria (CSU)”
> “The study is now complete.”

Source: [Celldex EAACI 2023 urticaria release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab)

<a id="topic-3.1.5.2-5"></a>

###### Congress presentations of the data in 2023

> “Data from this study were reported across multiple medical meetings, including the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in February 2023, the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress in June 2023 and the European Academy of Dermatology & Venereology (EADV) Congress in October 2023.”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Randomized, double-blind, placebo-controlled design with screening, treatment, and follow-up periods

> “This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.”
> “The study included the following periods: 2‐week screening, 12‐week treatment, and 12‐week posttreatment follow‐up (Figure S1).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.3-2"></a>

###### Four sequentially enrolled intravenous cohorts randomized 4:1

> “treated with intravenous barzolvolimab for 12 weeks with a 12‐week follow‐up in four sequentially enrolled cohorts (randomized 4:1 barzolvolimab:placebo)”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.3-3"></a>

###### Registry title: phase 1 multiple ascending dose add-on study

> “A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria”
> “There is a screening period of up to 2 weeks, a 12-week double-blind treatment period and a 12-week follow-up period after treatment.”

Source: [ClinicalTrials.gov NCT04538794](https://clinicaltrials.gov/study/NCT04538794)

<a id="topic-3.1.5.3-4"></a>

###### Follow-up for 12 weeks or until symptoms resumed

> “Following completion of the 12 week treatment period, patients were followed for an additional 12 weeks or until resumption of symptoms, whichever was sooner.”

Source: [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0)

<a id="topic-3.1.5.3-5"></a>

###### Dose and schedule selection from the single-dose healthy-volunteer study

> “Doses were selected based on results from the single‐dose healthy‐volunteer study [10], in which 0.3–9 mg/kg barzolvolimab was well tolerated and demonstrated dose‐dependent suppression of serum tryptase (Supporting Information Methods).”
> “Given the sustained tryptase suppression and prolonged serum half‐life observed in the single‐dose study, two dose schedules were evaluated: once every 4 weeks (Q4W) and every 8 weeks (Q8W).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.3-6"></a>

###### Sponsor role in design, data analysis, and manuscript preparation

> “This trial was designed and sponsored by Celldex Therapeutics.”
> “Data were collected by the trial investigators according to Good Clinical Practice guidelines and were analyzed by the sponsor.”
> “The first draft of the manuscript was written by a medical writer paid by the sponsor, with critical input and approval from all authors.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Inclusion criteria: age, disease activity, disease duration, and antihistamine use

> “Eligible patients were aged 18–75 years and had CSU refractory to H1 antihistamine at approved or increased doses alone or in combination with H2 antihistamine and/or leukotriene receptor antagonists (LTRA).”
> “Key inclusion criteria were moderate‐to‐severe CSU, defined as a weekly urticaria activity score (UAS7) of ≥ 16 (disease activity categories: 0, symptom free; 1–6, well‐controlled; 7–15, mild; 16–27, moderate; and 28–42, severe urticaria [11]); a weekly Hives Severity Score (HSS7) ≥ 8 (range: 0–21; higher values indicate greater severity) during the 7 days prior to randomization (Day 1); an in‐clinic UAS ≥ 4 on ≥ 1 screening visit days; antihistamine for treatment of CSU for at least 3 consecutive days immediately prior to the initial screening visit and were expected to use the antihistamines throughout the study period beginning at screening; CSU diagnosis for ≥ 6 months; and presence of itch and hives for ≥ 6 consecutive weeks at any time prior to enrollment despite concurrent use of antihistamine.”
> “Patients met defined hematology and chemistry criteria; had no other comorbidities that would introduce additional risk factors or interfere with study procedures; had no history of anaphylaxis; and had no known HIV, hepatitis B, or hepatitis C infection.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.4-2"></a>

###### Exclusion criteria: recent biologics, prior barzolvolimab, immunosuppressives, oral doxepin, and other itching skin disease

> “Key exclusion criteria were receipt of prior biologic therapy (e.g., omalizumab, dupilumab, and ligelizumab) within the past 3 months or prior treatment with barzolvolimab; treatment with immunosuppressives within 4 weeks/5 half‐lives; treatment with doxepin (oral) within 4 weeks prior to study treatment; and any other skin disease associated with chronic itching that might confound study evaluations and results.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.4-3"></a>

###### Prior biologic treatment permitted with washout

> “This is a randomized, double-blind, placebo-controlled, multiple ascending dose study in adults with moderate-to-severe chronic CSU (weekly urticaria activity score [UAS7] ≥16) refractory to H1 antihistamines; prior treatment with biologics permitted with washout.”

Source: [Maurer et al. (2023a)](https://celldex.com/wp-content/uploads/2025/06/Safety-and-Clinical-Activity-of-Multiple-Doses-of-Barzolvolimab-an-anti-KIT-Antibody-in-Patients-with-Chronic-Spontaneous-Urticaria.pdf)

<a id="topic-3.1.5.4-4"></a>

###### Registry criteria: blood counts, contraception for 150 days, live vaccines, pregnancy, and anaphylaxis

> “Normal blood counts and liver function tests.”
> “Both males and females of child-bearing potential must agree to use highly effective contraceptives during the study and for 150 days afterwards after treatment.”
> “Women who are pregnant or nursing.”
> “Vaccination with a live vaccine within 4 weeks prior to study drug administration (subjects must agree to avoid vaccination during the study).”
> “History of anaphylaxis.”

Source: [ClinicalTrials.gov NCT04538794](https://clinicaltrials.gov/study/NCT04538794)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Intravenous infusion every 4 or 8 weeks as add-on to antihistamines

> “Patients were randomly assigned in a 4:1 ratio to receive a 60‐min intravenous infusion of either barzolvolimab or placebo (saline) Q4W or Q8W according to their assigned cohort (1: 0.5 mg/kg Q4W; 2: 1.5 mg/kg Q4W; 3: 3.0 mg/kg Q8W; and 4: 4.5 mg/kg Q8W) over 12 weeks as add‐on treatment to H1 antihistamine either alone or in combination with H2 antihistamine and/or LTRA (administered prior to study drug infusion).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.5-2"></a>

###### Number of doses in each cohort

> “Barzolvolimab was administered intravenously at 0.5 mg/kg every 4 weeks (3 doses), 1.5 mg/kg every 4 weeks (3 doses), 3 mg/kg every 8 weeks (2 doses), 4.5 mg/kg every 8 weeks (2 doses), as add-on treatment to H1-antihistamines, either alone or in combination with H2-antihistamines and/or leukotriene receptor agonists.”

Source: [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0)

<a id="topic-3.1.5.5-3"></a>

###### Rescue medication

> “Rescue treatments were allowed up to maximum allowable doses: diphenhydramine 100 mg 4× daily (QID), hydroxyzine 50 mg QID, or H2 antihistamine 4× the recommended dose.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.5-4"></a>

###### Registry arms: CDX-0159 or normal saline every 4 to 8 weeks

> “CDX-0159 every 4-8 weeks”
> “Normal saline every 4-8 weeks”
> “Administered intravenously”

Source: [ClinicalTrials.gov NCT04538794](https://clinicaltrials.gov/study/NCT04538794)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Incidence of Adverse Events as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Registry primary outcome: incidence and severity of adverse events to Day 169

> “Safety as assessed by the incidence and severity of adverse events”
> “Safety of multiple, ascending doses of CDX-0159 as determined by drug related adverse events”
> “From Day 1 (first dose) to Day 169 (last follow-up visit)”

Source: [ClinicalTrials.gov NCT04538794](https://clinicaltrials.gov/study/NCT04538794)

<a id="topic-3.1.5.6.1-2"></a>

###### Safety assessments

> “Safety was assessed by the incidence and severity of treatment‐emergent adverse events (TEAEs) and serious AEs (SAEs), dose‐limiting toxicities, clinical laboratory tests, vital sign measurements, 12‐lead electrocardiograms, and physical examinations.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.6.1-3"></a>

###### Rationale: first multiple-dose study after single-dose studies

> “We report the effect of multiple ascending doses (MAD) of barzolvolimab on safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and clinical activity in CSU patients whose disease is inadequately controlled by antihistamines.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

> “Single dose studies have shown that barzolvolimab is generally well tolerated and has significant clinical activity in antihistamine refractory chronic inducible urticaria (CINDU), including biologic refractory, with profound suppression of circulating tryptase and depletion of skin MCs.”
> “Here we report safety and clinical activity data of a Phase 1 multiple-ascending dose trial of barzolvolimab in antihistamine refractory chronic spontaneous urticaria (CSU) patients.”

Source: [Maurer et al. (2023a)](https://celldex.com/wp-content/uploads/2025/06/Safety-and-Clinical-Activity-of-Multiple-Doses-of-Barzolvolimab-an-anti-KIT-Antibody-in-Patients-with-Chronic-Spontaneous-Urticaria.pdf)

> “We report results from the first multiple dose study of barzolvolimab in CSU patients.”

Source: [Maurer et al. (2023c)](https://celldex.com/wp-content/uploads/2025/06/EADV2023_Patients-With-Chronic-Spontaneous-Urticaria-Experience-Improvement-in-Quality-of-Life-When-Treated-With-Barzolvolimab-1.pdf)

<a id="topic-3.1.5.6.1-4"></a>

###### Registry secondary outcomes: pharmacokinetics, UAS7, HSS7, ISS7, UCT, stem cell factor, tryptase, and immunogenicity

> “CDX-0159 serum concentrations will be measured at specified visits”
> “The change from baseline for Urticaria Activity Score (UAS7) in patients who received CDX-0159 vs. placebo”
> “The change from baseline for Hives Severity Score (HSS7) in patients who received CDX-0159 vs. placebo”
> “The change from baseline for Itch Severity Score (ISS7) in patients who received CDX-0159 vs. placebo”
> “The change in baseline for Urticaria Control Test (UCT) in patients who received CDX-0159 vs. placebo”
> “The effect of CDX-0159 on stem cell factor levels”
> “The effect of CDX-0159 on tryptase”
> “Assessment of immunogenicity by measuring the development of anti- CDX-0159 antibodies”

Source: [ClinicalTrials.gov NCT04538794](https://clinicaltrials.gov/study/NCT04538794)

<a id="topic-3.1.5.6.1-5"></a>

###### Weekly urticaria activity score (UAS7): components, range 0 to 42, and disease activity categories

> “The UAS7 score is calculated as the sum over 7 days of the daily intensity of itch (ISS7 itch severity score) and number of hives (HSS7 hives severity score). UAS7 values range from 0 to 42, with higher values reflecting higher disease activity.”

Source: [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0)

> “disease activity categories: 0, symptom free; 1–6, well‐controlled; 7–15, mild; 16–27, moderate; and 28–42, severe urticaria”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.6.1-6"></a>

###### Urticaria Control Test (UCT): range 0 to 16, complete control at 16, well controlled at 12 or more

> “UCT has 4 items with 5 answer options (scored with 0-4 points); recall period of 4 weeks. Low points indicate high disease activity and low disease control. The minimum and maximum UCT scores are 0 and 16, with 16 points indicating complete disease control and ≥12 indicating well controlled disease.”

Source: [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0)

<a id="topic-3.1.5.6.1-7"></a>

###### Assessment ranges for UAS7, AAS7, UCT, and DLQI

> “Assessments: Safety, 7-day Urticaria Activity Score (UAS7; range 0-42), 7-day Angioedema Activity Score (AAS7; range 0-105), Urticaria Control test (UCT; range 0-16) , Dermatology Life Quality Index (DLQI; range 0-30), circulating Tryptase and Stem Cell Factor (SCF).”

Source: [Maurer et al. (2023b)](https://celldex.com/wp-content/uploads/2025/06/EAACI2023_CSU_Jun2023_Final.pdf)

<a id="topic-3.1.5.6.1-8"></a>

###### Physician Global Assessment (PhysGA): range 0 to 3

> “Physician Global Assessment (PhysGA; range 0-3)”

Source: [Maurer et al. (2023c)](https://celldex.com/wp-content/uploads/2025/06/EADV2023_Patients-With-Chronic-Spontaneous-Urticaria-Experience-Improvement-in-Quality-of-Life-When-Treated-With-Barzolvolimab-1.pdf)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Planned enrollment: approximately 40 participants in four cohorts

> “The study is expected to enroll approximately 40 patients with CSU across four cohorts (8 CDX-0159; 2 placebo).”

Source: [Celldex phase 1b CSU initiation release (2020)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-initiates-phase-1b-study-cdx-0159-chronic)

<a id="topic-3.1.5.7.1-2"></a>

###### Screened and randomized participants

> “A total of 74 patients were screened, of whom 45 were randomly assigned.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.7.1-3"></a>

###### Participants by cohort

> “0.5 mg/kg, Q4W (n = 9); 1.5 mg/kg, Q4W (n = 8); 3 mg/kg, Q8W (n = 9); and 4.5 mg/kg, Q8W (n = 9)”
> “All barzolvolimab (N = 35)”
> “Pooled placebo (N = 10)”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.7.1-4"></a>

###### Interim analysis population, May 2022 data cutoff

> “As of the data cut-off on May 23, 2022, 34 patients with CSU were enrolled and treated [26 barzolvolimab (n=9 in 0.5 mg/kg; n=8 in 1.5 mg/kg; n=9 in 3.0 mg/kg) and 8 placebo].”
> “The 0.5 mg/kg and 1.5 mg/kg cohorts had completed study participation through 24 weeks; 7 of 12 patients in the 3.0 mg/kg cohort had completed week 12; enrollment in the 4.5 mg/kg cohort was ongoing.”

Source: [Celldex phase 1b CSU EAACI release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-interim-data)

<a id="topic-3.1.5.7.1-5"></a>

###### Analysis population, November 2022 data cutoff

> “As of the data cut-off on November 29, 2022, enrollment was complete with 45 patients with moderate to severe CSU refractory to antihistamines enrolled and treated [35 barzolvolimab (n=9 in 0.5 mg/kg; n=8 in 1.5 mg/kg; n=9 in 3.0 mg/kg; n=9 in 4.5 mg/kg) and 10 placebo].”
> “The 0.5 mg/kg, 1.5 mg/kg and 3.0 mg/kg cohorts had completed study participation through 24 weeks; 6 of 9 patients in the 4.5 mg/kg cohort had completed through the week 20 visit.”

Source: [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Safety population: all participants who received at least one dose

> “The analysis population was the safety population, defined as all patients who received at least one dose of study treatment.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.7.2-2"></a>

###### Analysis by dose with placebo pooled across cohorts

> “Results were analyzed by dose and overall for patients who received barzolvolimab. The placebo group was pooled from each cohort. Baseline was defined as the last available measurement prior to study treatment administration. Change from baseline was calculated as the difference between postbaseline and baseline values.”
> “Safety was assessed separately by treatment group and as pooled active treatment. Analyses included the number and percentage of patients experiencing AEs, summarized by severity and relationship to study drug.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.7.2-3"></a>

###### Descriptive pharmacokinetic, antidrug antibody, and pharmacodynamic analyses

> “PK parameters were calculated using noncompartmental methods and summarized using descriptive statistics to compare exposure in single and multiple dose settings. The impact of antidrug antibodies (ADA) on drug levels and safety was evaluated by comparing the area under the concentration–time curve (AUC) and the incidence of AEs for ADA‐positive versus ADA‐negative patients in each treatment group, respectively. Summary statistics were descriptive and presented to evaluate PD changes.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.7.2-4"></a>

###### Analysis set and data included at the November 2022 data cutoff

> “All data were analyzed by treatment group (placebo patients pooled) for patients who received at least one dose of study treatment. Data cut 29NOV2022”
> “Complete data are included for all patients in dose levels through 3 mg/kg through 24 weeks.”

Source: [Maurer et al. (2023a)](https://celldex.com/wp-content/uploads/2025/06/Safety-and-Clinical-Activity-of-Multiple-Doses-of-Barzolvolimab-an-anti-KIT-Antibody-in-Patients-with-Chronic-Spontaneous-Urticaria.pdf)

<a id="topic-3.1.5.7.2-5"></a>

###### Company responder analyses: participants with missing data excluded, Week 24 shown only where at least 50% had data

> “Clinical responses shown are the proportion of patients with the defined response at the specific timepoint. Patients with missing data at the timepoint are excluded.”
> “Data for week 24 included only for dose levels with at least 50% of patients with data available at the timepoint; data not shown for 0.5 mg/kg and placebo dose levels as most patients had significant symptoms ahead of week 24 and discontinued follow up.”

Source: [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Completion of the 12-week treatment period

> “Overall, 42 patients (93.3%) completed treatment (Figure S2). Three patients did not complete the treatment period: one in the barzolvolimab 4.5‐mg/kg group because of low white blood count (WBC), and two in the placebo group who sought alternate treatment for CSU because of symptom severity.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.1-2"></a>

###### Doses not received and follow-up discontinuation, November 2022 data cutoff

> “As of the data cut-off on November 29, 2022, enrollment was complete”
> “Data for the 0.5 mg/kg and placebo group are only included through week 12 because, as expected, most patients from these groups had significant symptoms ahead of week 24 and discontinued follow up. Two patients did not receive all doses of study treatment [4.5 mg/kg (1), placebo (1)].”

Source: [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Demographics and baseline disease characteristics by cohort

| Characteristic | 0.5 mg/kg Q4W (N = 9) | 1.5 mg/kg Q4W (N = 8) | 3.0 mg/kg Q8W (N = 9) | 4.5 mg/kg Q8W (N = 9) | All barzolvolimab (N = 35) | Pooled placebo (N = 10) |
| --- | --- | --- | --- | --- | --- | --- |
| Age, years, mean (range) | “43.8 (21–73)” | “53.3 (29–75)” | “49.4 (26–65)” | “51.1 (29–68)” | “49.3 (21–75)” | “49.8 (18–70)” |
| Female, n (%) | “6 (67)” | “7 (88)” | “6 (67)” | “9 (100)” | “28 (80)” | “7 (70)” |
| BMI, kg/m2, mean (range) | “31.1 (26.0–36.0)” | “37.8 (28.6–58.9)” | “29.4 (22.3–36.9)” | “27.1 (21.5–34.4)” | “31.2 (21.5–58.9)” | “31.8 (16.4–55.2)” |
| CSU duration, years, mean (range) | “7.5 (0.6–41.1)” | “17.1 (2.6–61.3)” | “4.8 (0.6–21.3)” | “10.4 (1.0–35.4)” | “9.7 (0.6–61.3)” | “5.6 (1.4–13.1)” |
| Prior H2-antihistamine, n (%) | “6 (67)” | “4 (50)” | “4 (44)” | “6 (67)” | “20 (57)” | “4 (40)” |
| Prior leukotriene receptor antagonist, n (%) | “3 (33)” | “2 (25)” | “0 (0)” | “3 (33)” | “8 (23)” | “2 (20)” |
| Prior omalizumab, n (%) | “4 (44)” | “3 (38)” | “4 (44)” | “2 (22)” | “13 (37)” | “6 (60)” |
| UAS7, mean (range) | “31.1 (20.0–39.0)” | “29.5 (20.0–40.6)” | “29.4 (16.3–42.0)” | “28.3 (22.0–38.0)” | “29.6 (16.3–42.0)” | “35.8 (19.0–42.0)” |
| AAS7 positive at baseline, n (%) | “5 (56)” | “6 (75)” | “7 (78)” | “8 (89)” | “26 (74)” | “5 (50)” |
| AAS7 in those positive at baseline, mean (range) | “29.0 (4.0–59.5)” | “43.3 (1.0–79.0)” | “29.8 (3.0–49.0)” | “33.7 (6.0–80.0)” | “34 (1.0–80.0)” | “53.2 (3.5–80.5)” |
| UCT, mean (range) | “1.7 (0–4)” | “2.4 (1–8)” | “3.1 (0–7)” | “4.7 (1–12)” | “3.0 (0–12)” | “3.4 (0–11)” |
| Tryptase, ng/mL, mean (range) | “5.0 (2.0–10.3)” | “6.3 (2.8–15.1)” | “8.6 (3.3–28.8)” | “5.5 (2.3–10.2)” | “6.2 (2.0–28.8)” | “5.3 (3.2–7.5)” |

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.2-2"></a>

###### Disease severity, prior omalizumab and biologic use, and angioedema history

> “Patients had high mean (range) baseline CSU activity, with UAS7 = 29.6 (16.3–42.0) for barzolvolimab‐treated, UAS7 = 35.8 (19.0–42.0) for placebo‐treated, and 44% prior omalizumab use.”
> “The majority had an inadequate response to omalizumab.”
> “There were no notable differences between the barzolvolimab and placebo groups in the demographic or clinical characteristics at baseline (Table 1). Most patients had severe disease per UAS7. A total of 44% of patients had prior use of biologics. The percentage of patients with a history of angioedema was similar between placebo (50%) and across the barzolvolimab groups (60%), with mean baseline angioedema activity score over 7 days (AAS7) of 26.6 and 26.0, respectively.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.2-3"></a>

###### Race, ISS7, HSS7, and total IgE at the November 2022 data cutoff

> “Data cut 29NOV2022”

Source: [Maurer et al. (2023a)](https://celldex.com/wp-content/uploads/2025/06/Safety-and-Clinical-Activity-of-Multiple-Doses-of-Barzolvolimab-an-anti-KIT-Antibody-in-Patients-with-Chronic-Spontaneous-Urticaria.pdf)

| Characteristic | 0.5 mg/kg Q4W (N= 9) | 1.5 mg/kg Q4W (N= 8) | 3.0 mg/kg Q8W (N= 9) | 4.5 mg/kg Q8W (N= 9) | All barzolvolimab (N= 35) | Pooled placebo (N= 10) |
| --- | --- | --- | --- | --- | --- | --- |
| Race, White, n (%) | “6 (67)” | “7 (88)” | “9 (100)” | “7 (78)” | “29 (83)” | “7 (70)” |
| Race, African American, n (%) | “3 (33)” | “1 (13)” | “0 (0)” | “1 (11)” | “5 (14)” | “3 (30)” |
| Race, Other, n (%) | “0 (0)” | “0 (0)” | “0 (0)” | “1 (11)” | “1 (3)” | “0 (0)” |
| Prior angioedema, n (%) | “5 (56)” | “5 (63)” | “5 (56)” | “6 (67)” | “21 (60)” | “5 (50)” |
| ISS7, mean (range) | “15.7 (11.0 - 21.0)” | “15.5 (12.0 - 21.0)” | “14.6 (1.2 - 21.0)” | “15.4 (10.5 -19.0)” | “15.3 (1.2 - 21.0)” | “19.3 (12.0 - 21.0)” |
| HSS7, mean (range) | “15.4 (8.0 - 21.0)” | “14.0 (8.0 - 21.0)” | “14.8 (8.0 - 21.0)” | “12.4 (7.0 -19.0)” | “14.1 (7.0 - 21.0)” | “16.5 (7.0 - 21.0)” |
| UAS7, mean (range) | “31.1 (20.0 - 39.0)” | “29.4 (20.0 - 40.6)” | “29.4 (16.3 - 42.0)” | “27.8 (17.5 - 38.0)” | “29.4 (16.3 - 42.0)” | “35.8 (19.0 - 42.0)” |
| Total IgE, kU/L, mean (range) | “80 (2 - 239)” | “161 (13 - 328)” | “337 (4 - 1371)” | “88 (2 - 307)” | “165 (2 - 1371)” | “161 (5 - 409)” |

Source: [Maurer et al. (2023a)](https://celldex.com/wp-content/uploads/2025/06/Safety-and-Clinical-Activity-of-Multiple-Doses-of-Barzolvolimab-an-anti-KIT-Antibody-in-Patients-with-Chronic-Spontaneous-Urticaria.pdf)

<a id="topic-3.1.5.8.2-4"></a>

###### Baseline DLQI and PhysGA by cohort

| Characteristic | 0.5 mg/kg Q4W (N= 9) | 1.5 mg/kg Q4W (N= 8) | 3.0 mg/kg Q8W (N= 9) | 4.5 mg/kg Q8W (N= 9) | All barzolvolimab (N= 35) | Pooled placebo (N= 10) |
| --- | --- | --- | --- | --- | --- | --- |
| DLQI, mean (range) | “13.2 (7-24)” | “15.1 (5-24)” | “7.8 (1-15)” | “9.7 (1-16)” | “11.3 (1-24)” | “13.5 (1-26)” |
| PhysGA, mean (range) | “1.9 (1-3)” | “2.3 (1-3)” | “2.7 (2-3)” | “2.1 (1-3)” | “2.2 (1-3)” | “2.1 (1-3)” |

Source: [Maurer et al. (2023c)](https://celldex.com/wp-content/uploads/2025/06/EADV2023_Patients-With-Chronic-Spontaneous-Urticaria-Experience-Improvement-in-Quality-of-Life-When-Treated-With-Barzolvolimab-1.pdf)

<a id="topic-3.1.5.8.2-5"></a>

###### Prior omalizumab use in interim company reports, May 2022 and November 2022 data cutoffs

> “As of the data cut-off on May 23, 2022, 34 patients with CSU were enrolled and treated”
> “42% of patients treated with barzolvolimab had prior omalizumab and had similar symptom improvement as overall population”

Source: [Celldex phase 1b CSU EAACI release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-interim-data)

> “As of the data cut-off on November 29, 2022, enrollment was complete”
> “37% of treated patients had prior omalizumab therapy and still had similar clinical benefit improvement as the overall population”

Source: [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Week 12 UAS7 complete response (UAS7 = 0) and well-controlled disease (UAS7 ≤ 6), all barzolvolimab doses versus placebo

> “UAS7 response to barzolvolimab was greater than placebo: 71.4% of barzolvolimab‐treated patients had a well‐controlled response (UAS7 ≤ 6) by Week 12, compared with 30.0% of placebo‐treated patients (Figure 1C), and 57.1% of barzolvolimab‐treated patients had a complete response (UAS7 = 0) by Week 12 compared with 20% of placebo‐treated patients (Figure 1D).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.3-2"></a>

###### Week 12 UCT well-controlled disease (UCT ≥ 12) and complete response (UCT = 16), all barzolvolimab doses

> “Overall, 77.1% of barzolvolimab‐treated patients achieved a well‐controlled response (UCT ≥ 12), and 42.9% of the patients who received barzolvolimab achieved a complete response (UCT = 16) by Week 12.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.3-3"></a>

###### UAS7, HSS7, ISS7, and UCT change from baseline from Week 1 through Week 24

> “Urticaria symptoms measured by change from baseline in UAS7 improved by Week 1 (Figure 1A) for all barzolvolimab dose levels compared with placebo. Sustained improvement of UAS7 scores through Week 24 was seen for the groups ≥ 1.5 mg/kg. HSS7 and ISS7, the two components of UAS7 score, showed comparable improvement in each urticaria symptom measurement by Week 1 and sustained improvement of scores through Week 24 for the ≥ 1.5‐mg/kg groups (Figure S4). Sustained improvement was also observed by change from baseline in UCT (Figure 1B).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.3-4"></a>

###### Week 24 urticaria-free status (UAS7 = 0) at doses of 1.5 mg/kg or more, 16 weeks after the last dose

> “As tryptase levels were suppressed, improvement in UAS7 was observed within 1 week, and > 50% of patients at doses ≥ 1.5 mg/kg remained urticaria free at Week 24, 16 weeks after their last dose.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.3-5"></a>

###### Transient response at the lowest dose (0.5 mg/kg)

> “The lowest dose (0.5 mg/kg) showed transient improvements in clinical activity that correlated with partial tryptase suppression, SCF increases, and subsequent recovery prior to the following dose.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.3-6"></a>

###### Prior omalizumab subgroup: Week 12 UAS7 = 0 and UAS7 ≤ 6, pooled doses of 1.5 mg/kg or more

> “A subgroup analysis of patients who had previously received omalizumab had a similar response profile (UAS7 and UCT) to those who were naive to omalizumab (Figure 3); the majority of experienced patients had discontinued prior omalizumab because of a lack of symptom control. Doses ≥ 1.5 mg/kg were pooled in barzolvolimab‐treated patients, and a complete response (UAS7 = 0) and well‐controlled response (UAS7 ≤ 6) by Week 12 were observed in 53.8% and 84.6% of barzolvolimab‐treated patients with prior omalizumab treatment, respectively, which is similar to the overall group.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

> “Oma Naïve n=17”
> “Oma Experienced n=9”
> “Pooled data from saturating doses (1.5, 3.0 and 4.5 mg/kg)”

Source: [Maurer et al. (2023b)](https://celldex.com/wp-content/uploads/2025/06/EAACI2023_CSU_Jun2023_Final.pdf)

<a id="topic-3.1.5.8.3-7"></a>

###### Authors' comparison with omalizumab registrational trials at Week 12

> “A total of 71% of barzolvolimab‐treated patients across doses achieved a well‐controlled (UAS7 ≤ 6) response, and 57% of the patients achieved a complete response (UAS7 = 0) during the first 12 weeks (compared with 36% of participants treated with omalizumab 300 mg Q4W in registrational trials at 12 weeks [12]); this was sustained through Week 24.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.3-8"></a>

###### Pooled doses of 1.5 mg/kg or more: UAS7 = 0 and UAS7 ≤ 6 at Weeks 12 and 24

> “Complete response (Urticaria free) at doses ≥ 1.5 mg/kg:”
> “56% of patients at Week 12”
> “55% of patients at Week 24”
> “Well controlled Urticaria at doses ≥ 1.5 mg/kg:”
> “64% of patients at Week 12”
> “60% of patients at Week 24”
> “Well Controlled Urticaria UAS7 ≤ 6”

Source: [Maurer et al. (2023b)](https://celldex.com/wp-content/uploads/2025/06/EAACI2023_CSU_Jun2023_Final.pdf)

<a id="topic-3.1.5.8.3-9"></a>

###### Week 12 UAS7 and UCT by cohort, November 2022 data cutoff

> “As of the data cut-off on November 29, 2022, enrollment was complete”
> “Mean reduction from baseline in urticaria activity (UAS7) at week 12 of 67% in the 1.5 mg/kg dose group (n=8), 67% in the 3.0 mg/kg dose group (n=9) and 82% in the 4.5 mg/kg dose group (n=9).”
> “Complete response (UAS7=0) at week 12 of 57% in the 1.5 mg/kg dose group, 44% in the 3.0 mg/kg dose group and 67% in the 4.5 mg/kg dose group.”
> “Well-controlled disease (UCT≥ 12) at week 12 of 75% in the 1.5 mg/kg dose group, 63% in the 3.0 mg/kg dose group and 89% in the 4.5 mg/kg dose group.”

Source: [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0)

<a id="topic-3.1.5.8.3-10"></a>

###### Pooled doses of 1.5 mg/kg or more: UAS7 = 0 at Weeks 12 and 20, November 2022 data cutoff

> “Data cut 29NOV2022”
> “56% of patients treated with doses ≥1.5 mg/kg achieved complete response at week 12 and 68% at week 20 with additional follow up ongoing for patients treated with 4.5 mg/kg.”

Source: [Maurer et al. (2023a)](https://celldex.com/wp-content/uploads/2025/06/Safety-and-Clinical-Activity-of-Multiple-Doses-of-Barzolvolimab-an-anti-KIT-Antibody-in-Patients-with-Chronic-Spontaneous-Urticaria.pdf)

<a id="topic-3.1.5.8.3-11"></a>

###### Week 24 UAS7 and UCT by cohort, complete 24-week data

> “At EAACI 2023, Celldex presented data on the complete 24 week experience for the 4.5 mg/kg cohort and data on angioedema impact across all study cohorts.”
> “Mean reduction from baseline in urticaria activity (UAS7) at week 24 was 80% in the 1.5 mg/kg dose group (n=7), 70% in the 3.0 mg/kg dose group (n=6) and 77% in the 4.5 mg/kg dose group (n=7).”
> “Complete response (UAS7=0) at week 24 was 57% in the 1.5 mg/kg dose group, 67% in the 3.0 mg/kg dose group and 43% in the 4.5 mg/kg dose group.”
> “Well-controlled disease (UCT≥ 12) at week 24 was 75% in the 1.5 mg/kg dose group, 67% in the 3.0 mg/kg dose group and 67% in the 4.5 mg/kg dose group.”

Source: [Celldex EAACI 2023 urticaria release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab)

<a id="topic-3.1.5.8.3-12"></a>

###### Week 24 maintenance of a Week 12 complete response (UAS7 = 0), doses of 1.5 mg/kg or more

> “During post-treatment follow up, 71% (10 of 14) of patients who had been treated with doses greater than or equal to 1.5 mg/kg and had a complete response (UAS7=0) at Week 12, remained urticaria free at Week 24 (patients received last dose of barzolvolimab at Week 8).”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="topic-3.1.5.8.3-13"></a>

###### Interim Week 8 and Week 12 UAS7 and UCT results, May 2022 data cutoff

> “As of the data cut-off on May 23, 2022, 34 patients with CSU were enrolled and treated”
> “Mean reduction from baseline in urticaria activity (UAS7) of 66.6% in all patients in the 1.5 mg/kg dose group (n=8) at week 12 and 75.1% in all patients in the 3.0 mg/kg dose group (n=9) at week 8 (reflects one dose; ongoing), demonstrating clinically meaningful symptom improvements for patients.”
> “Complete response (UAS7=0) of 57.1% in the 1.5 mg/kg dose group at week 12 and 44.4% at week 8 (reflects one dose; ongoing) in the 3 mg/kg dose group which is a key therapeutic goal.”
> “75% well-controlled disease by Urticaria Control Test (UCT) in the 1.5 mg/kg dose group at week 12 and 83.3% in the 3 mg/kg dose group at week 8 (reflects one dose; ongoing).”
> “As predicted, the lowest dose of 0.5 mg/kg resulted in suboptimal clinical activity compared to the higher doses.”

Source: [Celldex phase 1b CSU EAACI release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-interim-data)

<a id="topic-3.1.5.8.3-14"></a>

###### Angioedema: AAS7 improvement and angioedema-free participants (AAS7 = 0) at Weeks 12 and 24

> “The AAS7 results demonstrated rapid, durable symptom improvement in angioedema in the barzolvolimab groups (Figure S5).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

> “31 patients on study (n=26 barzolvolimab; 5=placebo) reported angioedema activity at baseline when enrolling in the study. 86% of the barzolvolimab treated patients at 1.5 mg/kg or greater were angioedema free at week 12 and 83% were angioedema free at week 24.”

Source: [Celldex EAACI 2023 urticaria release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab)

> “Angioedema free patients* at doses ≥ 1.5 mg/kg:”
> “Angioedema free AAS7* = 0”
> “Only patients who reported angioedema activity at baseline”

Source: [Maurer et al. (2023b)](https://celldex.com/wp-content/uploads/2025/06/EAACI2023_CSU_Jun2023_Final.pdf)

<a id="topic-3.1.5.8.3-15"></a>

###### Physician Global Assessment (PhysGA) from Week 1 through Week 24

> “Physician Global Assessment (PhysGA) showed decreases starting at Week 1 (mean baseline score for pooled barzolvolimab group = 2.2 vs. 0.6 [Week 1]), which were sustained through Week 24 (Week 24 = 0.8 [1.5 mg/kg], 0.4 [3.0 mg/kg], and 0.6 [4.5 mg/kg]; Figure S6B).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.3-16"></a>

###### Pharmacokinetics: exposure through 24 weeks and dose-linear Cmax and AUC

> “Multiple doses of barzolvolimab resulted in prolonged exposure through 24 weeks in the ≥ 1.5‐mg/kg dose levels (Figure 2A). Maximum serum concentration (Cmax) and AUC increased in a linear fashion with increasing dose (Table S1). Increased clearance and lower volumes of distribution were observed in patients who received lower doses.”
> “Barzolvolimab levels accumulated through multiple dosing cycles at all dose levels, and exposure by Cmax and AUC increased linearly with dose.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.3-17"></a>

###### Pharmacodynamics: serum tryptase suppression and plasma SCF increase

> “Serum tryptase, a specific marker for MCs, was suppressed at all barzolvolimab doses, and reduction below assay detection levels was generally observed at doses ≥ 1.5 mg/kg (Figure 2B). Maximal tryptase suppression and clinical activity were reached at doses ≥ 1.5 mg/kg, which are consistent with target saturation. Plasma SCF increases mirrored the tryptase suppression kinetics, and both correlated well with clinical activity (Figure 2C).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.5.8.4-1"></a>

###### DLQI through Week 24 at doses of 1.5 mg/kg or more

> “Decreases in the Dermatology Life Quality Index (DLQI) mean scores for the ≥ 1.5‐mg/kg barzolvolimab groups were sustained through Week 24 (baseline score = 11.3 in pooled barzolvolimab group vs. Week 24 mean scores = 1.3 [1.5 mg/kg], 3.2 [3.0 mg/kg], and 2.0 [4.5 mg/kg]; Figure S6A).”
> “The increased symptom control observed with barzolvolimab was reflected in the quality of life measurements, which showed profound improvement between Weeks 1 and 4 that was sustained through Week 24.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.4-2"></a>

###### DLQI decrease within 4 weeks in all barzolvolimab groups

> “A rapid decrease in the DLQI was noted within 4 weeks in all barzolvolimab treated patients.”
> “DLQI improvement was sustained at doses ≥1.5 mg/kg.”
> “DLQI and PhysGA trended closely with the dose-dependent improvement in UAS7 and UCT, tryptase suppression, and increases in SCF.”

Source: [Maurer et al. (2023c)](https://celldex.com/wp-content/uploads/2025/06/EADV2023_Patients-With-Chronic-Spontaneous-Urticaria-Experience-Improvement-in-Quality-of-Life-When-Treated-With-Barzolvolimab-1.pdf)

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Treatment-emergent adverse events through 24 weeks: incidence, infusion-related events, interruptions, and discontinuations

> “Overall, 30 barzolvolimab‐treated patients (86%) and 6 placebo‐treated patients (60%) experienced a TEAE. In the 1.5‐mg/kg group, two barzolvolimab‐treated patients (6%) experienced infusion‐related TEAEs. One patient (3%) in the 3.0‐mg/kg group experienced a TEAE that led to drug interruption. No patients experienced a dose‐limiting toxicity or any TEAE that led to treatment discontinuation.”
> “Most AEs were mild or moderate in severity and resolved while on study.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.5-2"></a>

###### TEAEs in at least 10% of barzolvolimab-treated participants by cohort at 24 weeks

| TEAE, n (%) | 0.5 mg/kg Q4W (N = 9) | 1.5 mg/kg Q4W (N = 8) | 3.0 mg/kg Q8W (N = 9) | 4.5 mg/kg Q8W (N = 9) | All barzolvolimab (N = 35) | Pooled placebo (N = 10) |
| --- | --- | --- | --- | --- | --- | --- |
| Any TEAE | “8 (89)” | “7 (88)” | “9 (100)” | “6 (67)” | “30 (86)” | “6 (60)” |
| Neutropenia | “2 (22)” | “2 (25)” | “1 (11)” | “0 (0)” | “5 (14)” | “0 (0)” |
| Leukopenia | “1 (11)” | “1 (13)” | “1 (11)” | “0 (0)” | “3 (9)” | “0 (0)” |
| Diarrhea | “1 (11)” | “0 (0)” | “1 (11)” | “1 (11)” | “3 (9)” | “0 (0)” |
| Fatigue | “1 (11)” | “1 (13)” | “0 (0)” | “1 (11)” | “3 (9)” | “1 (10)” |
| Infections and infestations | “1 (11)” | “4 (50)” | “5 (56)” | “4 (44)” | “14 (40)” | “2 (20)” |
| COVID-19 | “0 (0)” | “1 (13)” | “2 (22)” | “2 (22)” | “5 (14)” | “0 (0)” |
| Nasopharyngitis | “0 (0)” | “1 (13)” | “2 (22)” | “1 (11)” | “4 (11)” | “1 (10)” |
| Urinary tract infection | “1 (11)” | “2 (25)” | “1 (11)” | “0 (0)” | “4 (11)” | “0 (0)” |
| Arthralgia | “2 (22)” | “0 (0)” | “0 (0)” | “1 (11)” | “3 (9)” | “0 (0)” |
| Back pain | “0 (0)” | “1 (13)” | “2 (22)” | “0 (0)” | “3 (9)” | “0 (0)” |
| Headache | “2 (22)” | “0 (0)” | “2 (22)” | “1 (11)” | “5 (14)” | “2 (20)” |
| Hair color changes | “0 (0)” | “1 (13)” | “3 (33)” | “5 (56)” | “9 (26)” | “0 (0)” |

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.5-3"></a>

###### Hair color changes: locations and resolution

> “Hair color change was the most common event, experienced by nine barzolvolimab‐treated patients (26%; Table 2); hair color changes occurred in different locations: scalp, beard, and body hair; and seven patients had this TEAE resolve by the end of the study.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.5-4"></a>

###### Taste changes

> “Taste changes, as noted in prior barzolvolimab studies, were reported by three patients (< 10%).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.5-5"></a>

###### Infections and their relation to neutrophil decreases

> “A total of 40% of barzolvolimab‐treated patients and 20% of placebo‐treated patients experienced an infection AE. The infections that were reported by > 10% of barzolvolimab‐treated patients were COVID‐19 (14%), nasopharyngitis (11%), and UTI (11%), and were not correlated with neutrophil decreases.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.5-6"></a>

###### Serious adverse event: grade 4 salmonella gastroenteritis assessed as unrelated

> “One SAE of Grade 4 salmonella gastroenteritis in a 59‐year‐old Black woman (1.5‐mg/kg group) was assessed by the investigator as unrelated to study treatment; she was treated with Levaquin, was discharged, and completed the study as planned.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.5-7"></a>

###### Hematologic decreases after the first dose and grade 3 shifts

> “Decreases in leukocytes, absolute neutrophil count, hemoglobin, and platelets were observed in patients after the first barzolvolimab dose when compared with placebo; no additional decreases were observed after subsequent doses (Figure S3). The majority of shifts were to Grades 1 and 2. A patient who received 4.5‐mg/kg barzolvolimab experienced a Grade 3 decrease in platelets; there was one patient also in the 4.5‐mg/kg group who experienced a Grade 2 decrease in WBC and did not receive the second dose per protocol; and three patients experienced Grade 3 decreased neutrophils (one in the 1.5‐mg/kg group and two in the 4.5‐mg/kg group); these all resolved during the study. There was no correlation of decreases with dose level. There were no trends of neutropenia correlating with increased infections.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.5-8"></a>

###### Immunogenicity: antidrug antibodies in 57% without apparent effect on exposure or safety

> “Fifty‐seven percent (20/35) of patients were ADA positive, and the proportion of patients who experienced drug‐related AEs was similar in ADA‐positive and ADA‐negative patients.”
> “Treatment‐emergent ADA were observed in 57% of barzolvolimab‐treated patients, without apparent impact on exposure.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.5-9"></a>

###### Immunogenicity: antidrug antibodies in 51%, November 2022 data cutoff

> “Data cut 29NOV2022”
> “Treatment-emergent ADA observed in 51% of patients receiving study drug, without apparent impact on exposure.”

Source: [Maurer et al. (2023a)](https://celldex.com/wp-content/uploads/2025/06/Safety-and-Clinical-Activity-of-Multiple-Doses-of-Barzolvolimab-an-anti-KIT-Antibody-in-Patients-with-Chronic-Spontaneous-Urticaria.pdf)

<a id="topic-3.1.5.8.5-10"></a>

###### KIT-mediated adverse events and expected recovery after drug clearance

> “The observed AEs in barzolvolimab‐treated patients reflect KIT‐mediated toxicities and were reversible, consistent with the expected effects of KIT inhibition. The most common AE related to treatment with barzolvolimab was mild hair color changes, followed by mild‐to‐moderate neutropenia, which was not associated with infections.”
> “All KIT‐dependent functions, including tissue MCs, hematological parameters, and hair color changes, are expected to recover once KIT signaling resumes following drug clearance, as has been observed in prior studies with barzolvolimab.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-3.1.5.8.5-11"></a>

###### Adverse events in at least 10% of barzolvolimab-treated participants, November 2022 data cutoff

> “Data cut 29NOV2022”
> “Includes preferred terms: urinary tract infection, cystitis, and bacteriuria”

Source: [Maurer et al. (2023a)](https://celldex.com/wp-content/uploads/2025/06/Safety-and-Clinical-Activity-of-Multiple-Doses-of-Barzolvolimab-an-anti-KIT-Antibody-in-Patients-with-Chronic-Spontaneous-Urticaria.pdf)

| AE, n (%) | 0.5 mg/kg Q4W (N= 9) | 1.5 mg/kg Q4W (N= 8) | 3.0 mg/kg Q8W (N= 9) | 4.5 mg/kg Q8W (N= 9) | All barzolvolimab (N= 35) | Pooled placebo (N= 10) |
| --- | --- | --- | --- | --- | --- | --- |
| Any AE | “8 (89)” | “7 (88)” | “9 (100)” | “6 (67)” | “30 (86)” | “5 (50)” |
| Hair color changes | “0 (0)” | “1 (13)” | “3 (33)” | “4 (44)” | “8 (23)” | “0 (0)” |
| COVID-19 | “0 (0)” | “1 (13)” | “2 (22)” | “2 (22)” | “5 (14)” | “0 (0)” |
| Headache | “2 (22)” | “0 (0)” | “2 (22)” | “1(11)” | “5 (14)” | “1 (10)” |
| Neutropenia | “2 (22)” | “2 (25)” | “1 (11)” | “0 (0)” | “5 (14)” | “0 (0)” |
| Urinary tract infection, cystitis, and bacteriuria | “1 (11)” | “2 (25)” | “2 (22)” | “0 (0)” | “5 (14)” | “0 (0)” |

Source: [Maurer et al. (2023a)](https://celldex.com/wp-content/uploads/2025/06/Safety-and-Clinical-Activity-of-Multiple-Doses-of-Barzolvolimab-an-anti-KIT-Antibody-in-Patients-with-Chronic-Spontaneous-Urticaria.pdf)

<a id="topic-3.1.5.8.5-12"></a>

###### Urinary tract infection grouped with cystitis and bacteriuria in a later congress poster

> “Includes preferred terms: urinary tract infection, cystitis, and bacteriuria.”

Source: [Maurer et al. (2023c)](https://celldex.com/wp-content/uploads/2025/06/EADV2023_Patients-With-Chronic-Spontaneous-Urticaria-Experience-Improvement-in-Quality-of-Life-When-Treated-With-Barzolvolimab-1.pdf)

| AE, n (%) | 0.5 mg/kg Q4W (N= 9) | 1.5 mg/kg Q4W (N= 8) | 3.0 mg/kg Q8W (N= 9) | 4.5 mg/kg Q8W (N= 9) | All barzolvolimab (N= 35) | Pooled placebo (N= 10) |
| --- | --- | --- | --- | --- | --- | --- |
| Urinary tract infection, cystitis, and bacteriuria | “1 (11)” | “3 (38)” | “3 (33)” | “0 (0)” | “7 (20)” | “0 (0)” |

Source: [Maurer et al. (2023c)](https://celldex.com/wp-content/uploads/2025/06/EADV2023_Patients-With-Chronic-Spontaneous-Urticaria-Experience-Improvement-in-Quality-of-Life-When-Treated-With-Barzolvolimab-1.pdf)

<a id="topic-3.1.5.8.5-13"></a>

###### Interim safety, May 2022 data cutoff

> “As of the data cut-off on May 23, 2022, 34 patients with CSU were enrolled and treated”
> “Most AEs were mild or moderate in severity and resolved while on study, with none leading to treatment discontinuation. The most common treatment emergent adverse events were urinary tract infections, headache, neutropenia and back pain. UTIs, headache and backpain were all reported as unrelated to treatment.”
> “Four patients with screening and baseline neutrophil counts at the lower end of the normal range on study initiation had decreases in neutrophil counts reported as AEs.”

Source: [Celldex phase 1b CSU EAACI release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-interim-data)

<a id="topic-3.1.5.8.5-14"></a>

###### Neutrophil decreases reported as adverse events and hematologic recovery, November 2022 data cutoff

> “As of the data cut-off on November 29, 2022, enrollment was complete”
> “Changes in hematologic parameters were consistent with observations in single dose studies, with no pattern of further decreases with multiple doses; hematologic values generally remained within the normal range and returned to baseline levels during the follow up period. Five patients had decreases in neutrophil counts reported as AEs; four of which were previously reported in the EAACI 2022 data presentation.”
> “UTIs and COVID-19 were reported as unrelated to treatment.”

Source: [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

- Author-stated limitations: “This study was limited by the small sample size and variation in drugs used for background urticaria treatment”, with participants required to be on a stable regimen before barzolvolimab administration.
- Sample size and design: 45 participants were randomized, 35 to barzolvolimab in four sequentially enrolled cohorts of 8 or 9 and 10 to placebo pooled from each cohort (4:1 within cohorts). Analyses of pharmacokinetics, antidrug antibodies, and pharmacodynamics were descriptive.
- Applicability of dosing: barzolvolimab was given as a 60-minute intravenous infusion at 0.5 to 4.5 mg/kg every 4 or 8 weeks for 12 weeks; the phase 3 trials use subcutaneous 150 mg every 4 weeks or 300 mg every 8 weeks after a loading dose. The registry title calls the study phase 1, and the publication calls it phase 1b.
- Follow-up and missing data: follow-up lasted 12 weeks or until symptoms resumed. Company responder analyses excluded participants with missing data at a timepoint and showed Week 24 only for dose levels with at least 50% of participants with data; data for 0.5 mg/kg and placebo were included only through week 12 because most of those participants had significant symptoms ahead of week 24 and discontinued follow up. Two placebo participants did not complete treatment because they sought alternate treatment for symptom severity.
- Baseline differences: mean UAS7 was 35.8 in the placebo group and 29.6 in the barzolvolimab group, and prior omalizumab was recorded in 6 (60%) placebo and 13 (37%) barzolvolimab participants in Table 1; the publication states there were no notable differences between groups at baseline.
- Antidrug antibodies, by document: 57% (20/35) in the publication; 51% in the November 2022 data cutoff poster.
- Hair color changes, by document: 9 (26%) in the publication; 8 (23%) in the November 2022 poster.
- Any adverse event with placebo, by document: 6 (60%) in the publication; 5 (50%) in the November 2022 poster.
- Urinary tract infection, by document: 4 (11%) in the publication; 5 (14%) in the November 2022 poster and 7 (20%) in the EADV 2023 poster, both of which group urinary tract infection, cystitis, and bacteriuria.
- Prior omalizumab, by document: 44% in the publication's summary statement; 37% of treated participants in the company release reporting the November 2022 data cutoff; 42% of barzolvolimab-treated participants at the May 2022 data cutoff.
- Baseline AAS7, by document: 26.6 (placebo) and 26.0 (barzolvolimab) in the publication text; 53.2 (placebo) and 34 (barzolvolimab) among participants AAS7 positive at baseline in Table 1.
- Disposition, by document: three participants did not complete the treatment period (publication); two did not receive all doses of study treatment (company release reporting the November 2022 data cutoff).
- The omalizumab-experienced subgroup at pooled doses of 1.5 mg/kg or more is n=9 in the EAACI 2023 poster.
- Sponsor role: the trial was designed and sponsored by Celldex Therapeutics, data were analyzed by the sponsor, and the first draft of the manuscript was written by a medical writer paid by the sponsor.
- External comparison: the publication sets the 57% Week 12 complete response beside 36% for omalizumab 300 mg Q4W in registrational trials at 12 weeks.

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/); [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023); [ClinicalTrials.gov NCT04538794](https://clinicaltrials.gov/study/NCT04538794); [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0); [Celldex phase 1b CSU EAACI release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-interim-data); [Maurer et al. (2023a)](https://celldex.com/wp-content/uploads/2025/06/Safety-and-Clinical-Activity-of-Multiple-Doses-of-Barzolvolimab-an-anti-KIT-Antibody-in-Patients-with-Chronic-Spontaneous-Urticaria.pdf); [Maurer et al. (2023b)](https://celldex.com/wp-content/uploads/2025/06/EAACI2023_CSU_Jun2023_Final.pdf); [Maurer et al. (2023c)](https://celldex.com/wp-content/uploads/2025/06/EADV2023_Patients-With-Chronic-Spontaneous-Urticaria-Experience-Improvement-in-Quality-of-Life-When-Treated-With-Barzolvolimab-1.pdf); [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
